      
The COMET -PCOS trial - Comparing the effects of Oral Contraceptive Pills versus 
Metformin in the medical management of overweight/obese women with Polycystic 
Ovary Syndrome   
 
[STUDY_ID_REMOVED]  
November 30, 2021   
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
 
 
The COMET -PCOS trial - Comparing the effects of Oral Contraceptive Pills versus 
Metformin in the medical management of overweight/obese women with Polycystic 
Ovary Syndrome  
 
(COMET -PCOS)  
 
Principal Investigator (1): Anuja Dokra, MD, PhD  
Principal Investigator (2): Richard S. Legro, MD  
Principal Investigator (3): Monica Mainigi, MD 
 
Version 10.1 
 
Supported by:  
 
Potential R01 from the NIH  
 
 
Study Intervention Provided by:  No outside support  
Sponsor of IND(IDE):  Not Applicable  
 
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
Prepared by:  
The University of Pennsylvania Women’s Health Clinical Research Center  
Perelman School of Medicine  
3701 Market Street  
Philadelphia, PA 19104  
 
(215) 615- 0085  
 
Last updated: November 30 , 202 1 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Protocol Subcommittee  
 
 
 
Name  E-mail  
Anuja Dokras, MD  ADokras@obgyn.upenn.edu   
Richard Legro, MD  rsl1@psu.edu  
Christos Coutifaris, MD  CCoutifaris@uphs.upenn.edu  
  
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Table of Contents  
1 STUDY SYNOPSIS  ............................................................................................................................................. 7  
1.1 OBJECTIVES  ..................................................................................................................................................... 7  
1.2 HYPOTHESIS  ..................................................................................................................................................... 7  
1.3 PATIENT POPULATION  ...................................................................................................................................... 7  
1.4 STUDY DESIGN  ................................................................................................................................................. 7  
1.5 TREATMENT  ..................................................................................................................................................... 7  
1.6 PRIMARY EFFICACY PARAMETER  ...................................................................................................................... 7  
1.7 SECONDARY EFFICACY PARAMETERS  ............................................................................................................... 8  
1.8 STATISTICAL ANALYSIS  ................................................................................................................................... 8  
1.9 ANTICIPATED TIME TO COMPLETION  ................................................................................................................ 8  
1.10 REGULATORY COMPLIANCE  ............................................................................................................................. 8  
2 STUDY OBJECTIVES  ......................................................................................................................................... 9  
2.1 PRIMARY AIM .................................................................................................................................................. 9  
2.2 SECONDARY AIM ............................................................................................................................................. 9  
2.3 TERTIARY AIMS ............................................................................................................................................... 9  
3 BACKGROUND  ............................................................................................................................................... 10 
3.1 RATIONALE  .................................................................................................................................................... 10 
3.2 TREATMENT OF PCOS  ................................................................................................................................... 10 
3.3 METABOLIC SYNDROME IN PCOS .................................................................................................................. 11 
3.4 EFFECT OF OCP  ON METS .............................................................................................................................. 11 
3.5 HDL -C FUNCTION AND LIPOPROTEIN ANALYSIS IN PCOS  ............................................................................. 12 
3.6 IMPACT OF OCP  VS. METFORMIN ON HDL -C FUNCTION AND LIPOPROTEIN ANALYSIS IN PCOS  .................... 12 
3.7 PCOS  AND ADIPOCYTE DYSFUNCTION  ........................................................................................................... 13 
3.8 OCP  USE IN WOMEN WITH PCOS  ................................................................................................................... 13 
3.9 METFORMIN AS AN ALTERNATIVE TREATMENT FOR WOMEN WITH PCOS  ...................................................... 14 
3.10 OCP  VS. METFORMIN  ..................................................................................................................................... 14 
3.11 OCP  VS. METFORMIN VS . OCP  + METFORMIN  ................................................................................................ 14 
3.12 EFFECTS OF OCP  VS. METFORMIN VS OCP  + METFORMIN ON INDIVIDUAL COMPONENTS OF METS ............... 15 
3.13 DYSLIPIDEMIA ................................................................................................................................................ 15 
3.14 VISCERAL ADIPOSITY  ..................................................................................................................................... 15 
3.15 ADIPOKINE AND CYTOKINE SECRETION  .......................................................................................................... 16 
4 STUDY DESIGN  .............................................................................................................................................. 18 
4.1 OVERVIEW  ..................................................................................................................................................... 18 
4.1.1  Treatment Design  ..................................................................................................................................... 18 
4.1.2  Study Population  ...................................................................................................................................... 18 
5 SELECTION AND ENROLLMENT OF SUBJECTS ............................................................................................... 19 
5.1 INCLUSION CRITERIA  ..................................................................................................................................... 19 
5.2 EXCLUSION CRITERIA  .................................................................................................................................... 19 
5.3 STUDY TERMINATION CRITERIA  .................................................................................................................... 20 
5.4 STUDY ENROLLMENT PROCEDURES  ............................................................................................................... 20 
5.4.1  Recruitment ............................................................................................................................................... 20 
5.5 PROCEDURES FOR TRACKING SOURCES OF SUBJECTS AND THEIR DISPOSITION  ............................................. 21 
5.6 OBTAINING INFORMED CONSENT  ................................................................................................................... 22 
5.7 INTERVENTION GROUP ASSIGNMENT  ............................................................................................................. 22 
6 STUDY INTERVENTIONS  ................................................................................................................................ 22 
6.1 INTERVENTIONS , ADMINISTRATION AND DURATION  ...................................................................................... 22 
6.2 CONCOMITANT INTERVENTIONS  .................................................................................................................... 25 
6.3 ADHERENCE ASSESSMENT  ............................................................................................................................. 25 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 7 CLINICAL AND LABORATORY EVALUATIONS  ................................................................................................ 25 
7.1 SCHEDULE OF EVALUATIONS  ......................................................................................................................... 25 
7.2 TIMING OF EVALUATIONS  .............................................................................................................................. 26 
4. REVIEW ADVERSE EVENTS  .................................................................................................................................... 28 
6. COLLECT MEDICATION  ................................................................................... ERROR ! BOOKMARK NOT DEFINED . 
4. FASTING BLOOD DRAW AND SAFETY LABS  ................................................................................................................ 30 
6. PCOSQ,  CESD -R, STAI ..................................................................................................................................... 30 
10. REVIEW ADVERSE EVENTS  .............................................................................. ERROR ! BOOKMARK NOT DEFINED . 
11. COLLECT LOGS AND MEDICATION  ..................................................................... ERROR ! BOOKMARK NOT DEFINED . 
12. COGNITIVE QUESTIONNAIRES .......................................................................... ERROR ! BOOKMARK NOT DEFINED . 
8 STUDY RISK AND BENEFITS  ........................................................................................................................... 30 
8.1 RISK ............................................................................................................................................................... 30 
8.2 PROTECTION AGAINST RISKS ......................................................................................................................... 32 
8.3 POTENTIAL BENEFITS OF THE PROPOSED RESEARCH TO HUMAN SUBJECTS AND OTHERS  ............................. 34 
8.4 IMPORTANCE OF THE KNOWLEDGE TO BE GAINED  ......................................................................................... 34 
9 STATISTICAL CONSIDERATIONS .................................................................................................................... 36 
9.1 GENERAL DESIGN ISSUES  ............................................................................................................................... 36 
9.2 RANDOMIZATION  ........................................................................................................................................... 36 
9.3 OUTCOMES  ..................................................................................................................................................... 36 
9.3.1  Primary Outcome Measurements  ............................................................................................................. 36 
9.3.2  Secondary Outcome Measurements  .......................................................................................................... 36 
9.4 SAMPLE SIZE AND ACCRUALS  ........................................................................................................................ 36 
9.4.1  Sample Size and Power Calculations  ....................................................................................................... 36 
9.4.2  Statistical Analysis  .................................................................................................................................... 37 
9.4.3  Accrual  ..................................................................................................................................................... 38 
10 DATA COLLECTION, MONITORING AND ADVERSE EXPERIENCE REPORTING  ............................................. 38 
10.1 RECORDS TO BE KEPT  ..................................................................................................................................... 38 
10.1.1  Maintenance/Retention of site records  ..................................................................................................... 39 
10.1.2  Data Security  ............................................................................................................................................ 39 
10.2 ADVERSE EVENT REPORTING  ......................................................................................................................... 39 
10.2.1  Serious Adverse Events  ............................................................................................................................. 39 
10.3 DATA MONITORING  ....................................................................................................................................... 40 
10.4 STUDY MONITORING  ...................................................................................................................................... 40 
11 HUMAN SUBJECTS PROTECTION  ................................................................................................................. 41 
11.1 INSTITUTIONAL REVIEW BOARD (IRB)  REVIEW AND INFORMED CONSENT  ................................................... 41 
11.2 SUBJECT CONFIDENTIALITY  ........................................................................................................................... 41 
11.3 STUDY MODIFICATION /DISCONTINUATION  .................................................................................................... 41 
11.4 DATA AND SAFETY MONITORING BOARD  ...................................................................................................... 42 
12 REFERENCES  .................................................................................................................................................. 43 
 
FIGURE 1.  PREVALENCE OF METS IN WOMEN WITH PCOS,  GEOGRAPHICALLY MATCHED CONTROLS AND AGED 
MATCHED NHANES  POPULATION  ................................................................................................. 10  
 
 
TABLE 2: RANDOMIZATION FASTING BLOOD TESTS ................................................................................... 28  
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Acronyms  
 
American College of Cardiology  ACC 
Adverse Event  AE 
Cardiovascular Disease  CVD  
Data Monitoring Committee  DMC  
Diabetes Mellitus  DM 
Data Safety Monitoring Board  DSMB  
Insulin Resistance  IR 
Lifestyle Modification  LSM  
Metabolic Syndrome  MetS  
Oral Contraceptive Pills  OCP  
Polycystic Ovary Syndrome  PCOS  
Oral Glucose Tolerance Test  OGTT  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Study Synopsis  
 
Objectives  
To determine the effect of Oral Contraceptive Pills (OCP) verses Metformin verses OCP and Metformin on the 
prevalence of Metabolic Syndrome (MetS) and its components in overweight/obese women with Polycystic Ovary Syndrome (PCOS).  
 
Hypothesis  
OCPs increase the risk of MetS specifically by producing an atherogenic lipoprotein phenotype, increasing blood pressure and/ or body weight while metformin modestly decreases MetS risk by decreasing body weight and 
improving lipid phenotype. The combination of OCP and metformin (OCP, through lowering androgens, and 
metformin, through improvement in insulin sensitivity) will likely decrease the prevalence of MetS, thereby altering the risk profile for the development of diabetes and possible cardiovascular disease (CVD) in young women with PCOS.  
  
Patient Population  
The population will consist of 240 overweigh/obese women with hyperandrogenic PCOS, age 18 -40 years old.  
Subjects must have a body mass index (BMI) between 25 -48 kg/m².  Subjects will be diagnosed with PCOS defined 
by the Rotterdam criteria.  
 
Study Design  
This will be a three -arm, double -blind, double -dummy, multicenter, prospective, randomized clinical trial 
comparing OCP + placebo vs. Metformin + placebo vs. OCP + Metformin on the prevalence of MetS in women with PCOS.  This 6 -month study will consist of a screening visit, followed by 5 study visits. No longer term follow -up is 
planned.    
Treatment  
The intervention will consist of randomizing subjects to one of three arms.  Subjects will either be assigned to OCP + Placebo, Metformin + Placebo or OCP + Metformin. Metformin will be initiated in a step -up fashion using 
extended release pills as  they are associated with fewer gastrointestinal side effects.  Subjects will begin with one 
tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg. In regards to OCP, p revious randomized clinical trials (RCTs) have shown that 20mcg 
ethinyl estradiol/norethindrone 1.0 mg was well tolerated.  The study will utilize a 20mcg OCP but a less androgenic third generation progestin (desogestrel 0.15mg) with potentially lesser impact on l ipids and insulin sensitivity.  All 
subjects with no menses the 3 months prior to screening will be given medroxyprogesterone acetate, at the screening visit, after a negative pregnancy test (in order to induce menses).  Placebo pills will be administered to individuals randomized to OCP or metformin only in order to maintain study blinding.  Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. P atient contact will be made  
via the subject’s preferred contact method  after randomization and at the end of each month when there is no in 
person visit to ensure study compliance with medications, keeping study logs and to review side effects.  
 
Primary efficacy parameter  
Determine the prevalence of MetS after randomizing to OCP, metformin or OCP+metformin for 6 months. MetS will be defined by NCEP ATPIII criteria as the presence of at least 3 of the following 5 criteria: TG≥150mg/dl, HDL -
C<50mg/dl, BP ≥130/ ≥85mmHg, WC>88cm and fasting glucose ≥100mg/dl . 
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Secondary/Tertiary efficacy parameters  
Assess change in HDL -C function, serum apolipoproteins, lipid particle size and number, body fat distribution, 
BMI, serum adipokines, HbA1c, glucose and insulin sensitivity, serum markers of inflammation, free fatty acids, 
androgens, quality of life parame ters, cognitive testing and predictive factors for change in prevalence on MetS.  
 
Subjects will have the option to consent to storage of their blood for future additional analysis as related to the 
disease of interest.  No research/future analysis will take place, prior to gaining IRB approval.  
 
Statistical Analysis  
The primary analysis will use an intent -to-treat paradigm, wherein all randomized subjects are included according 
to their randomized treatment arm.  Data will be summarized using descriptive statistics for continuous variables and frequency statistics for  categorical variables.  For the primary outcome of the presence of MetS at the end of 
the trial, logistic regression will be used with independent variables that include terms for the treatment arm and the 3 randomization stratification factors as covariates, with a contrast constructed to test for linear trend over the three treatment arms.  For secondary continuous outcomes, linear mixed -effect models will be fit to assess 
differences between the treatment arms with respect to changes in these outcomes o ver time.  The independent 
variables in the model will be treatment arm, time, the interaction of treatment and time and the 3 randomization stratification factors as covariates.    
 
Anticipated time to completion  
A total of 5 years (2017 -2022) is anticipated.  3.5 -year enrollment period (based on 3 subjects per site/month x 2 
sites), 6 -month treatment period followed by time for analyses and interpretation of the data.  
 
Regulatory Compliance  
A data safety and monitoring board, led by Dr. Kathleen Hoeger, has been established to ensure that patient safety and clinical study data and regulatory requirements are met regarding the Food and Drug Administration (FDA) code for federal regulations .  This trial is registered on http://www.clinicaltrials.gov
   
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Study Objectives  
 
Primary Aim  
Our primary goal is to determine the effect of 6 months’ treatment with OCP vs. metformin vs. OCP + metformin 
on prevalence of MetS and its components in overweight / obese women. Implicit in the primary aim is clearly defining MetS, by NCEP ATPIII criteria as the presence of at least 3 of the following 5 criteria: TG≥150mg/dl, HDL -
C<50mg/dl, BP ≥130/ ≥85mmHg, WC>88cm and fasting glucose ≥100mg/dl ; and the goal of tracking safety of our 
interventions throughout the  study (through safety lab evaluations, vital signs and diaries).  
 
Secondary Aim  
The study will assess secondary outcomes such as defining the effects of OCP (lowering androgens) verses metformin (improving insulin sensitivity) verses OCP + metformin on body fat distribution, glucose tolerance, adipokines and markers of inflammation.  
 
1. Assess change in HDL -C function by measuring reverse cholesterol efflux capacity.  
2. Compare changes in serum apoliproteins and lipid particle size and number.  
Tertiary Aims  
 
1. Compare changes in total and visceral body fat distribution (DXA) and serum adipokines in  the 3 arms and 
correlate with changes in serum and androgens and markers of insulin sensitivity.  
2. Identify changes in serum markers of inflammation and  free fatty acids.  
3. Compare changes in anxiety, depression and quality of life parameters in all 3 arms.  
4. Compare changes in cognitive function scores in all 3 arms.  
5. Comparing response to treatment with presence of DNA polymorphisms  
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Background  
 
Rationale  
 
Treatment of PCOS  
Controversy exists regarding the optimal, long term management of overweight/obese women with polycystic 
ovary syndrome not attempting pregnancy.  It is well known that these women are at increased risk for development of Type 2 diabetes, dyslipidemia, metabolic syndrome and possibly cardiovascular disease due to insulin resistance (IR) and maybe hyperandrogenism.  In addition, the extent that racial differences in b ody fat 
distribution and dyslipidemia contribute to the differential burden of chronic disease in PCOS is unclear.  Although 
preventive treatments with oral contraceptive pills or metformin are widely used, international surveys show 
prescribing patterns differ amongst treating physicians (i.e. gynecologist, endocrinologist, or pediatricians).  In addition to different effects on menstrual cyclicity and hyperandrogenism, it is now clear that these different medical approaches also have varied metabolic effe cts possibly leading to adverse health consequences.  For 
example, in a NICHD -funded study, the University of Pennsylvania, PCOS Center recently uncovered a greater 
than 2 -fold increase in MetS after treatment with low dose OCP for 4 months in overweight/o bese women with 
PCOS.  
 The few randomized clinical trials (RCTs) comparing OCP versus metformin use in overweight/obese women with PCOS show that with improvement in menstrual irregularity and hirsutism, OCP may increase metabolic risk by increasing triglycerides, blood pressure , body fat and weight.  Metformin on the other hand, improves metabolic 
profile by decreasing serum glucose, insulin, triglycerides and body weight, although it has modest effects on menstrual irregularity and hyperandrogenism.  These studies have several limitations including short study period, small numbers and the inclusion of Caucasian women only.  Moreover, none have evaluated the effect of 
interventions on the composite risk of MetS or examined underlying mechanisms leading to change in metabolic 
risk. It is clear that there are no evidence -based recommendations for the optimum and comprehensive medical 
management of overweight/obese women with PCOS.  The working hypothesis states that OCP, through lowering androgens, and metformin, through improvemen t in insulin sensitivity, will affect the prevalence of MetS thereby 
altering the risk profile for the development of diabetes and possible CVD in these young women.  
 
  
 
         
 
   Figure 1.  Prevalence of MetS in women with PCOS, geographically matched controls 
and aged matched NHANES population  
 

COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Metabolic Syndrome in PCOS 
In 2005, we reported that the age -adjusted prevalence of MetS was higher in women with PCOS (47.3%, 95% 
CI 35.3 -56.9%) compared to geographically matched controls (4.3 %, 95% CI 1.9 -7.6%, p < .001).  Even young 
women (< 30 years) had a high prevalence of MetS (Fig. 1).  PCOS phenotypes with hyperandrogenemia have a 
significantly higher prevalence or MetS compared to contro ls1,2,3. African Americans (AA) in the general 
population have less visceral adipose tissue (VAT) and lower TG levels compared to Caucasians4,5and our recent 
data shows significantly lower visceral fat measured in AA women compared to white women with PCOS . 
(Table1).  
 
Despite lower TG levels and less visceral adiposity, we found that AA women with PCOS ages 20 -34 years have 
significantly increased risk of MetS compared to White women6 indicating racial disparity in cardiometabolic 
risk factors (Table 2). Inclusion of AA women in studies examining metabolic outcomes in PCOS is therefore 
critical and we will stratify our randomization by race.  
 
 
Table 2. Racial 
Disparity in MetS   
N Metaboli
c 
Syndrom
e BMI≥3
0 
kg/m2  TG≥ 
150 
mg/dL  HDL 
≤ 50 mg/dL  BP≥ 
130/85  
mmHg  Glucos
e≥ 100 mg/dL  
PCOS White  2
 22.6 %  51.7
 24.6
 35.6%  31.9%  4.9%  
PCOS Black  6
 40 %**  72.7
  10.9
  76.6% 
 45.5% *  18.8%
 NHANES white  2
 14.9%  66.1
 15.5
 39.9%  3.3%  9.0%  
NHANES black  1
 16.6%  75.4
 9.9%  42.9%  10.6%*  8.3%  
 
 
Effect of OCP on MetS  
The OWL PCOS Study – We have recently completed an NIH funded study, OWL - PCOS at PENN and Hershey 
examining the effects of pretreatment with low dose OCP (20ug ethinyl estradiol) versus weight loss 
interventions for 16 weeks, on pregnancy rates in overweight/obese women with PCOS7. Surprisingly, the OCP 
arm showed a significant increase in MetS [OR=2.47; 95% CI 1.42, 4.27]; with no change in the intensive Lifestyle 
modification with pharmacotherapy arm [OR=1.18; 95% CI 0.63, 2.19)] or Combined arms [OR=0.72; 95% CI 0.44, 1.17]. The  conversion rate to MetS was 28% in the OCP arm with significant increase in TG levels, and trend 
towards increase in BP and fasting glucose levels. Interestingly, we noted a significant decrease in VAT after treatment with OCP (Table 3) but an increase in glucose AUC. Our study suggests early onset metabolic dysfunction only in the OCP group, and this was attenuated in the Combined group with the addition of lifestyle modification associated with weight loss.  We have previously shown that women with PCOS hav e a high risk for 
depressive disorders (OR 5.11 95% CI 1.26- 20.69; P<.03)
8 and this risk persists over time9. In the OWL -PCOS study 
there was in fact an improvement in depressive symptoms and health related quality of life scores with OCP 
treatment7. These findings underscore the need for a clinical trial to comprehensively compare the effectiveness 
of therapeutic alternatives with specific focus on metabolic outcomes in addition to gynecological, 
dermatological and mood changes. Understanding the associated pathophysiological changes will add great value to this clinical trial.  Table 1. Differences in BMI -matched AA and 
White women with PCOS  Mean (SD)  AA 
N=48  White  
N=48  Difference of 
means  P 
value  
Triglycerides mg/dl  96 (66 -120)  117 (96.5 -156.8)  0.7 (0.6, 0.9)  0.01  
% Fat in largest Visceral Fat region  46.2 (5.4)  48.7 (5.1)  -2.5 ( -4.3, -0.7) 0.01  
% Fat in middle Visceral Fat region  41.2 (5.1)  44.4 (4.9)  -3.2 ( -4.8, -1.6) <.001  
% Fat in inner -most Visceral Fat region  39.1 (4.9)  43.0 (4.9)  -3.9 ( -5.5, -2.3) <.001  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
Table 3. Effect of OCP on Visceral  Adipose 
Tissue  Mean Change from Baseline (95% 
CI) P-
valu
 Fat Tissue in largest Visceral Fat region (g)  -66.3 ( -127.1, -5.5) 0.03  
Fat Tissue in middle Visceral Fat region (g)  -47.9 ( -91.8, -4.1) 0.03  
Fat Tissue in inner -most Visceral Fat region 
(g) -40.0 ( -78.4, -1.5) 0.04  
 
HDL-C function and lipoprotein analysis in PCOS  
There is increasing evidence showing measures of HDL -C function are more useful than HDL -C levels as 
predictors of CVD risk10,11. In collaboration with Dr. Nehal Mehta, Chief of Inflammation and CV Medicine at 
NIH/NHLBI, we reported no difference in HDL -C levels but a significant reduction in cholesterol efflux 
capacity in PCOS women12 (Table 4). We found a significant negative association between testosterone 
levels and ApoA1 and HDL -C efflux. Women with PCOS also had significant elevation in the atherogenic 
particles, large VLDL and small LDL, independent of obesity12. 
 
 
 
Table 4. Standard 
lipid and Lipoprotein 
 PCOS n=124  Controls n=67  Difference of means  P value 
Total Cholesterol 
 192.5±37.9  189.7±34.5  -2.8(-13.9, 8.2)  0.6 
HDL-C mg/dL  54.7 ±16.1  57.5± 17.9  2.8 (-2.2, 7.9)  0.2 
LDL-C mg/dl  167.150.8 154.943.9 -12.7( -27.4,2.07)  0.09 
Triglycerides mg/dl  146.592.9 112.269.9**  -34.3 ( -60.4, -8.2) 0.01 
HDL-C function - 
Cholesterol efflux  
  0.96 
(0.86 -1.06)  1.05 
(0.91 -1.18)*  0.07 (0.17, 0.12)  0.005  
NMR spectroscopy  
Large VLDL nmol/L   
4.04±3.7   
2.37±1.73   
-1.6 (-2.7,-0.63)   
0.002  
VLDL particle size 
 49.58±6.04  46.78± 5.28  -2.7(-4.7,-0.88)  0.004  
Small LDL nmol/L  652.91 ±367.95  434.3± 280.7  -218.57( -330,-106) 0.0002  
 
 
Impact of OCP vs. metformin on HDL- C function and lipoprotein analysis in PCOS  
We have preliminary data using samples from the OWL PCOS study7 (OCP arm) and PPCOS1 study (metformin 
arm)111 showing significant increase in HDL -C efflux with both OCP and metformin treatments. (Table 5) However, 
this benefit is offset in the OCP group by a significant atherogenic effect, increased sLDL and VLDL particles.  
 
Table 5. Impact of 
OCP versus 
metformin on 
 OWL PCOS -OCP arm  n=34  PPCOS1 -Metformin arm n=98  
Mean Change from 
Baseline (95% CI)   
P-value  Mean Change from 
Baseline (95% CI)   
P-value  
HDL-C efflux  0.10 (0.05, 0.16)  0.001  0.08 (0.04, 0.11)  <.0001  
HDL-Cmg/dl  3.6 (0.1, 7.1)  0.04 2.2 (-0.2, 4.5)  0.07 
HDL-Particles  4.2 (1.9, 6.5)  0.0004  0.9 (-0.6, 2.5)  0.23 
LDL-Cmg/dl  11.7 (0.6, 22.7)  0.04 4.5 (-2.9, 11.8)  0.23 
LDL-particles nmol/L  222.8 (98.6, 347.1)  0.001  51.4 ( -31.4, 134.2)  0.22 
Small LDL nmol/L  190.1 (113.1, 267.1)  <.0001  13.3 ( -38.4, 64.9)  0.61 
Large VLDL nmol/L  206.2 (90.5, 321.9)  0.001  47.8 (-29.3, 125.0)  0.22 

COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
 
PCOS and adipocyte dysfunction  
We have reported significantly lower serum adiponectin and higher leptin12, hsCRP13 and FFA levels12 in women 
with PCOS reflecting adipocyte dysfunction. Adipose tissue is a major source of FFA and inflammatory 
cytokines14,15which are drivers of CRP production in the liver 16,17. 
Polycystic ovary syndrome (PCOS), which affects 5 -15% of reproductive age women, has been linked to a high 
prevalence of cardiometabolic risk factors, namely type 2 diabetes (DM), obesity, dyslipidemia and hypertension2. 
The co -occurrence of these risk factors suggests the existence of metabolic syndrome (MetS), a clinically validated 
marker for identifying high -risk subjects predisposed to cardiovascular disease (CVD)18,19. The CVD risks of Mets 
and DM have been shown to be higher in women20,21and more imp ortantly the association between MetS and 
CVD is shown to be more pronounced in younger women warranting aggressive preventive therapy14 
. In our own studies, the prevalence of MetS in women with PCOS is significantly increased from a young age23 and 
is higher in the hyperandrogenic phenotype3. In a meta -analysis, including 2,256 PCOS women and 4,130 controls, 
the OR for MetS was 2.2 (95% CI 1.36 -3.56) independent of obesity24.  
 
Longitudinal studies in this population demonstrate a persistent increase in risk of DM, dyslipidemia and 
hypertension over a twenty -year period10, an increase in serum markers of CVD25,26and evidence of subclinical 
atherosclerosis27. In addition, perimenopausal and post -menopausal women with symptoms suggestive of PCOS 
have a higher risk of CV events28,29further linking PCOS to CVD later in life. Finally, it should be highlighted that, in 
addition to health consequences, these metabolic comorbidities along with gynecological and dermatologic concerns, contribute significantly to the financial (~$4.36 billi on annually) and emotional burden of PCOS
30,31. 
Collectively, these data support the notion that PCOS is associated with significant CV risk starting in early 
reproductive life and possibly continuing through menopause. It is striking that evidence based data on treatments for overweight/obese women with PCOS not seeking pregnancy is descriptive, limited and mixed. In  fact, there are 
conflicting clinical guidelines from several medical societies
32,33,34for first line management recommending either 
oral contraceptive pills (OCP) or metformin (insulin sensitizer). Surprisingly, the increased risk of MetS in this ‘at risk’ population as a consequence of taking these medications was unknown till recently. In the OWL -PCOS study, 
an NIH funded RCT21 we recently reported an increased risk of MetS (OR=2.47; 95% CI 1.42, 4.27) in obese women treated with OCP for 16 weeks. It is clear that comprehensive treatments addressing common complaints such as 
menstrual irregularity and hirsutism whilst improving metabolic risk are urgently needed. It is therefore proposed COMET PCOS,  a randomized clinical trial to compare the effects of OC P vs. metformin vs. OCP+metformin on the 
risk of MetS in young overweight/obese women with PCOS . 
 
 
OCP use in women with PCOS  
OCP are effective first line therapy as they regulate menses and improve acne and hirsutism by significantly 
lowering bioavailable androgens in PCOS35,36. Decreasing androgens with OCP may have additional but relatively 
unexplored benefits in PCOS as elevated androgens may adversely affect insulin sensitivity, adipocyte function and fat distribution
37. Some studies in women without PCOS suggest that OCP use is associated with glucose 
intolerance38,39hypertension40, elevated CRP levels41,42and dyslipidemia (especially hypertriglyceridemia) 43,44. 
Therefore, it can be hypothesized that OCP use may increase CVD risk especially given the high prevalence of 
obesity (50- 80%) and hypertriglyceridemia in PCOS2. However, in a meta- analysis, treatment with OCP was 
associated with paradoxical changes in lipids, increase in triglycerides (TG) and high -density lipoprotein (HDL -C) 
levels, with no significant change in fasting glucose, low density lipoprotein (LDL -C) and insulin resistance (IR) in 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 women with PCOS45. Further the impact of only one abnormal metabolic risk factor versus clustering of metabolic 
components on long term risk of DM and CVD in this population is unknown. None of these studies have examined 
MetS, a validated predictor of cardiometabolic risk, as a composite outcome. In the OWL -PCOS study pre -
conception treatment of obese women with OCP resulted in an increased risk of MetS7. 
 
Metformin as an alternative treatment for women with PCOS  
Women with PCOS have a greater degree of insulin resistance (IR) compared to age and weight matched controls46 
with defects in insulin- mediated glucose transport47,48 and GLUT4 production49,50. Given the role of 
hyperinsulinemia/IR in the development of hyperandrogenism and disordered folliculogenesis, metformin is the 
most extensively used insulin sensitizing drug and often first line treatment of PCOS51,52. In the general population, 
it decreases the risk of DM and CV events in adults53,54and in children and adolescents with IR or pre -diabetes 
metformin improves insulin sensitivity55 and may reduce BMI56. Metformin use in PCOS improves the frequency 
of menses and decreases androgens but less effectively compared to OCP making it less desirable as a first line agent
57. However, metformin has a favorable impact on metabolic profile by decreasing fasting insulin and hsCRP 
levels, blood pressure53,58 and is associated with modes t weight loss in women with PCOS 59,60,61,62. These studies, 
which are limited by size, randomization and short treatment duration, although suggestive of improvement in 
metabolic risk, are not conclusive. Lifestyle modification, another first line treatment in PCOS, is associated with poor adherenc e and sustainability. In a meta -analysis (608 women) use of metformin with lifestyle changes was 
associated with significantly lower BMI and improved menstruation compared to lifestyle changes alone
63.  
 
OCP vs. metformin  
Very few RCTs have examined the effects of metformin versus OCP specifically in overweight/obese women with PCOS. A Cochrane systematic review (4 studies, 104 subjects) concluded that treatment with OCP is associated with improvement in menstrual pattern a nd serum androgen levels compared with metformin; but metformin use 
decreases fasting insulin and TG levels compared with OCP use
64,65,66,67,68. All these studies were conducted in 
Europe using a progestin that is not available in the US (cyproterone acetate) limiting the generalizability of these findings. These studies do not provide evidence for any single treatment of choice and lack data on important 
clinical outcomes such as the development of MetS or DM
69. 
 
OCP vs. metformin vs. OCP + metformin  
It is suspected that the combination of OCP+metformin may be an appropriate comparator to address 
gynecological, dermatologic and metabolic end points in PCOS. Only one clinical trial has included three arms 
namely OCP vs metformin vs OCP+metformin but included lean and obese women (n=65) with PCOS70 showing 
improvement in body fat distribution in the OCP+metformin arm71. 
 
This clinical trial examined traditional CV markers, lacked mechanistic data and most importantly was not powered to provide clear recommendations. Overall these limited data present a clinical conundrum and  underscore the 
need to answer important clinical questions; do OCP increase the risk of MetS in  overweight/obese women with 
PCOS, can metformin mitigate these effects and therefore will the  combination of OCP+metformin offer the best 
outcomes for improving menstrual regularity,  decreasing hyperandrogeni sm and improving CV risk?  
 Further complicating matters, PCOS treatment practice patterns vary depending on the physician (i.e. pediatrician, 
gynecologist or endocrinologist) treating adolescent and adult women with PCOS not seeking fertility. In physician 
surveys metformin was noted to be preferentially used by Australian and European endocrinologists
72,73while 
pediatricians and gynecologists practicing in the US frequently prescribed OCP as first line therapy74. Besides 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 competing guidelines from several international medical Societies, 32,33,34,75 there are no formal recommendations 
for CV risk stratification prior to prescribing these medications1. Although the  best therapeutic approach for MetS 
is lifestyle modification, such programs alone have high dropout rates  necessitating pharmacotherapy to achieve 
and maintain weight loss76. It is therefore critical to identify  appropriate medical therapy whilst avoiding 
medications that might alter the risk of MetS in this young but high risk population. The overall goal of COMET -
PCOS is to provide practitioners with evidence for the selection of  the most appropriate treatment for 
overweight/obese women with PCOS by carefully defining the clustering of  metabolic risks and benefits associated 
with three interventions - OCP, metformin or OCP+metformin.  
 
Effects of OCP vs. metformin vs OCP + metformin on individual components of MetS 
There is some controversy regarding the predictive value of clustering of risk factors i.e. MetS versus the individual 
risk factors being independently associated with DM/CVD77. Therefore, evaluating the effects of OCP and/or 
metformin on each component of MetS can provide critical and novel mechanistic insights about the pathways 
altered by these treatments.  
 
Dyslipidemia  
Although PCOS is associated with low HDL -C levels and high TG1 and OCP use increases both HDL -C and TG levels , 
it is not clear how the interaction of these diametrically opposite alterations impacts  the potential risk of coronary 
artery disease (CAD). While it may be beneficial that the estrogenic component of  OCP increases HDL -C78,79, drugs 
such as the cholesterol ester transfer protein inhibitor torcetrapib and niacin that increase HDL -C, have failed to 
reduce CV events in clinical trials80,81. Two large studies recently indicated  that HDL -C function may be a better 
marker of CVD outcomes independent of HDL -C levels10,11. We were the first to report significant reduction in 
cholesterol efflux capacity, a metric of  HDL-C function, in PCOS12. While  no gender differences have been described 
in HDL -C efflux82, it is unclear if hyperandrogenemia, IR or inflammation affects HDL -C function in PCOS83,84. Both 
hypertriglyceridemia, the commonest lipid abnormality  in PCOS, and loss of function mutations of Apo C3 are also 
predictive of CHD85,86. In IR states, adipocytes  increase free fatty acid (FFA) production14 and the liver subsequently 
increases TG and VLDL synthesis15 providing the substrate for increased atherogenic sma ll (s)LDL particles87,88. 
Lipoprotein subclass profiles  measured by nuclear magnetic resonance (NMR) spectroscopy are not fully apparent 
on a conventional lipid panel. sLDL and sHDL are associated with incident DM89 and IR90,91and are superior to 
standard LDL -C measurements in prediction of future CV events92. Of note, metformin therapy improved NMR 
measured lipoprotein profile in the Diabetes Prevention Study93. Therefore, as a secondary aim evaluating the 
effects of OCP, metformin and OCP+metformin on detailed lipid phenotyping will provide novel data to define the precise atherogenic impact of each study arm.  
 
Visceral adiposity  
Waist circumference is independently and strongly associated with DM, particularly in women
94,95. Young women 
with PCOS have a twofold increased risk of DM9 independent of obesity96. It is however unclear if visceral adiposity 
in PCOS is similar97,98,99or increased 100,101,102 compared to controls. Studies examining change in body fat 
distribution after medical treatment in PCOS are also few and contradictory. While androgens may predispose to 
central body fat distribution103, OCP use, despite a decrease in androgens, has been associated in some studies 
with an increase in total and visceral fat mass104,105,106. On the contrary, metformin increases insulin -mediated 
glucose uptake in visceral adipose tissue, thereby increasing the re -esterification of FFA107,108. However, clinical 
studies in PCOS also show mixed results on the effects of metformin on visceral adiposity70,109,110. These 
controversies underscore the need to systematically evaluate change in visceral fat distribution with OCP and/or 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 metformin use in order to understand its contribution to risk factors such as dyslipidemia, inflammation and 
altered glucose tolerance.  
 
Adipokine and cytokine secretion  
Visceral adiposity is associated with adipocyte dysfunction, characterized by inflammation and impaired 
adipokine secretion. Leptin secretion rises in parallel with fat expansion in adipocytes111 and elevated leptin 
levels have been described in PCOS compared to weight matched controls112. Adiponectin, on the other hand, 
which has insulin- sensitizing, anti- atherogenic and anti -inflammatory properties, and is inversely associated with 
MetS and independently predicts DM113, has been shown in a meta -analysis to be significantly lower in PCOS114. 
This observation was independent of obesity and testosterone, but associated with IR. The impact of metformin or OCP therapy on changes in adiponectin are mixed
67,68,69,115,116 possibly related to differential actions on the 
liver and adipose tissue. Adipocytes also secrete inflammatory cytokines and a meta- analysis confirmed 
significantly higher levels of hsCRP in PCOS25. Metformin treatment is associated with decreased hsCRP117 and IL -
6 levels in PCOS65,118. Precisely defining the effects of OCP and/or metformin use on adipokines and 
inflammatory cytokines will better assess the impact of these treatments on underlying pathophysiological 
processes associated with adipocyte dysfunction.  
 In summary, evaluation of MetS risk modification associated with treatments such as OCP and/or metformin in a high risk PCOS population is urgently needed and will have a major impact on current clinical practice.   
 
 
 
 
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Implications for the COMET -PCOS Trial  
This project brings together a multidisciplinary exceptionally well- qualified team with demonstrated expertise 
in reproductive endocrinology, cardiometabolic risk assessment and inflammation and clinical trials to study 
two major health issues namely, PCOS and MetS. Our study includes four highly innovative components:  
 
First Due to lack of evidence there is currently no consensus regarding the medical management of overweight/ 
obese women with PCOS. OCP and metformin, though currently in use, have differing treatment outcomes and 
safety profiles, resulting in conflicting guide lines for use in PCOS. COMET -PCOS will be the first 3 arm clinical trial 
to be adequately powered to provide evidence for single agent versus combination therapies for medical management of PCOS.  It will have significant impact on current clinical practice paradigms much like the impact 
of the PPCOS1 trial (Clomid versus metformin versus  clomid+metformin)111. 
 
Second Based on our recent findings from OWL -PCOS we have included MetS as a composite endpoint to provide 
comprehensive assessment of early CVD risk in this young  population.  
 
Third  We have included innovative mechanistic secondary aims and will apply novel concepts to the  assessment 
of dyslipidemia, the commonest metabolic abnormality in PCOS. We will measure HDL -C function (cholesterol 
efflux capacity) and lipoprotein particle size and number using NMR spectroscopy to clearly define the atherogenic impact of the three therapeutic  interventions.  
 Fourth Recognizing that there are racial disparities in metabolic components in PCOS, we will stratify the 
randomization  in our primary  aim by race.  This will provide  unique  observations  of potential  importance.  
 
     
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Study Design  
 
Figure 2: COMET -PCOS Study Flowchart  
 
 
Overview  
The flowchart ( Figure 2 ) summarizes this study which will consist of medical treatments commencing with 
randomization at equal allocation (1:1:1) to three interventions OCP, metformin and OCP+metformin for a 
duration of 6 months. The primary outcome will be change in prevalence of Mets in each group. The secondary outcomes include assessment of HDL -C efflux, lipoprotein particle size and number, glucose tolerance, body fat 
distribution and measurements of markers of inflammation.  
Treatment Design  
This will be a three -arm, multi- center, prospective randomized trial of three types of medication treatment in 
overweight/obese women with hyperandrogenic PCOS who will be randomized to either OCP + placebo, metformin + placebo or OCP + metformin.  All subjects will also receive lifestyle modification counseling regarding diet and exercise.  
The appropriate study candidates will be recruited from the University of Pennsylvania (Penn) or Pennsylvania State University, Hershey Medical Center (PSU).  Recruited subjects will meet the inclusion and exclusion criteria detailed below.  Monitoring of this trial at both sites will be conducted by the Penn designated monitor  for the 
Women’s Health Clinical Research Center at the University of Pennsylvania, with progress reports provided to the Data and Safety Monitoring Board (DSMB) no less than every twelve months in order to review trial progress and subject safety.  
Study Population  
Two- hundred forty (240) overweight/obese women with hyperandrogenic PCOS not seeking pregnancy, age 18 -
40 years, will be enrolled in the participating sites.  The overall goal of the inclusion/exclusion criteria is to identify a population of healthy women who are between 25 -48 kg/m².  Subjects will have a history of androgen excess 
and chronic anovulation or PCO appearing ovaries.  If existing medical records are used to verify inclusion or exclusion criteria, the site should keep a copy of these in the so urce documents.  A one -month wash -out period (6 
month wash out in the case of injectable hormonal contraceptive) will be required for medications prior to screening (most common OCP and metformin).  Medications that subjects are required to wash -out are in cluded 
in the MOP and questions can be directed to the Principal Investigator at each site.  

COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Selection and Enrollment of Subjects  
 
Inclusion Criteria  
 
1. Women ≥ 18 to ≤ 40 years of age (at the time of screening), with hyperandrogenic PCOS.  
2. Subjects will be diagnosed with PCOS defined by the  most up to date  Rotterdam criteria based on:  
a. Androgen excess  
And 
b.  polycystic ovaries.  
Or 
c. A history of chronic anovulation or spontaneous periods . 
 
3. BMI ≥ 25 kg/m² to ≤ 4 8 kg/m² obtained at screening visit.  
4. In good general health according to the investigators discretion  
5. Willing to avoid pregnancy for the duration of the study.  
 
Exclusion Criteria  
 
1. Current pregnancy or desire of pregnancy during course of study  
2. Currently breastfeeding  
3. Known 21 hydroxylase deficiency or any form of congential adrenal hyperplasia (CAH)  
4. Untreated thyroid disease (TSH ≤0.45 mlU/mL and ≥ 4.5 mlU/mL)  
5. Untreated hyperprolactinemia (2 Levels≥30 ng/ml at least one week apart)  
6. Type 1 or type 2 Diabetes Mellitus currently receiving anti -diabetic agents, (subjects may wash out from 
metformin if taking the drug for another indication.)  
7. Liver disease (AST/ALT≥2 times normal or a total bilirubin ≥2.5 mg/dL)  
8. Renal disease (BUN≥30 mg/dL or serum creatinine ≥1.4 mg/dL)  
9. Anemia (hemoglobin ≤10 mg/dL)  
10. current history of alcohol abuse ( ≥ 22 drinks/week in the past 3 months)  
11. Poorly controlled hypertension defined as average systolic blood pressure >= 150 mm Hg or average 
diastolic ≥100 mm Hg obtained on three measurements obtained 5 minutes apart. If treated, average systolic blood pressure ≥140 mm Hg or average diastolic ≥90 mm Hg  
12. Patients with a history of, or suspected cervical carcinoma, endometrial carcinoma  
13. TG≥250mg/dl  
14. Current Use of lipid lowering or weight loss agents  
15. Current use of hormonal contraceptives such as oral contraceptives, depo progestin, or hormonal implants  
16. Participation in any study of an investigational drug or device or biological agent within 30 days  
17. Suspected adrenal or ovarian tumor secreting androgens  
18. Suspected Cushing’s syndrome  
19. Bariatric surgery procedure in the recent past (≤12 months)  
20. Absolute contraindications to the use of hormonal contraceptives or metformin (details in MOP)  
22. subjects who are unable to comply with the study procedures, (In the opinion of the investigator, )  
*Note:  the study will allow rescreening of subjects. When subjects are re -screened a new consent form will be 
signed and a new study number will be assigned.  
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Study Termination Criteria  
1. Development of diabetes as defined in the manual of procedures  
2. Development of hypertension as defined in the manual of procedures  
3. Unable to tolerate study medications due to side effects  
4. Pregnancy (women found to be pregnant will be referred to prenatal care)  
5. Miss more than 2 consecutive visits (unless excused by the PI)  
 
 
Study Enrollment Procedures  
Recruitment  
We do not anticipate difficulty with the completion of this trial as our study team has demonstrated the ability to 
recruit a similar population in several previous trials (PCOS studies completed by UPenn and PSU: OWL -
PCOS/PPCOS1 /PPCOS2). At both sites we  have expert investigators in PCOS to improve external validity and to 
help overcome any possible recruitment barriers. Subjects recruited at UPenn are drawn from a four state area 
including Pennsylvania, New Jersey, Delaware, and Maryland. Dr. Dokras dire cts the Penn PCOS center which is 
located at 2 sites (Philadelphia city and in a suburban location - Radnor) and she sees approximately 1000 
visits/year exclusively for PCOS. UPenn also has a high patient volume in Reproductive Endocrinology with 22,000 pa tient visits per year. Hershey Medical Center is the only academic medical center between Philadelphia 
and Pittsburgh with a large referral area. They have recruited subjects from areas as far away as Scranton/Wilkes Barre (90 miles) to the northeast, and Altoona (150 miles) to the West, Harrisburg (12 miles), York (30 miles), Lancaster (20 miles), State College (90 miles), Williamsport (90 miles), and Allentown (85 miles).   The location of the two sites, University of Pennsylvania (UPenn) in an urban setting, and Hershey Medical Center (PSU) in a rural/suburban setting will allow us to recruit from a representative sample of the population.  
 
Clinical Practices of Investigators  
Women presenting to the clinical practices of Dr. Dokras, Dr. Mainigi,  and Dr. Legro for consultation for PCOS (after 
clinical confirmation of their potential eligibility for admission into the study based on inclusion and exclusion criteria) will be approached to participate by the research coordinator or non -care providing  physician.  In the 
recruitment visit, study details including the intervention will be explained.  Risks and benefits will be thoroughly discussed and consents given to the patient prior to any study procedures being performed. The drugs being 
utilized in this study are commonly used in current practice and may be familiar to the women interested in 
participating in the study.   
Hospital/Local Health Care Referrals  
Subjects will be recruited at each site from individual practice(s) of the investigators as noted above as well as faculty/resident clinics.  Ongoing contact with practice and faculty members as well as with residents will be made by the investigators and coordinators, reminding them of the inclusion criteria, importance of the study, etc.  In addition, the investigators will describe the study to members of other departments in the hospital, primarily family practice, medical endocrinology, and gynecology who also see and treat these patients.  Contact with local physicians will be made and/or grand rounds will be given to disseminate information about the study. Letters will be mailed or emailed to potential subjects which provides details of the study and contact information of the study team (to allow for subject to reach out for more information). Penn Datastore  as well as electronic medical record 
(EMR) recruitment tools such as SlicerDicer and best practice announcements (BPA)  (and PSU , CHOP  equivalent s) 
may be utilized to provide a list of potential subjects based on clinical practice information.   
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
Referrals from Study Participants  
Study participants often refer friends, acquaintances and colleagues to be potential participants.  
A subject referral- based payment structure will be added to increase recruitment. Prior study participants who have given 
their permission for re -contact that are not Penn Employees will be contacted to give them the opportunity to refer 
individuals to our  study. For each individual referred who qualifies as eligible, the prior participant will get $25. The referral 
period will last until the study team determines the budget to support this type of referral is no longer available. The stud y 
team will inform the prior participants at that time of the ending of the referral- based payment program.  
 
Previous Study Participants  
The trial will be offered to women who have previously participated in clinical trials offered by the study team, 
who have consented to be contacted for future participation via their preferred contact method (after confirmation of their potential eligibility for admission into the study based on inclusion and exclusion criteria).  
Local Advertisements  
Advertisements will be placed in local newspapers and run on local television networks / radio near Penn and PSU and will be continued on a regular basis if response is good. SEPTA advertising through regional rail, Market -
Frankford line and Broad Street L ine has been a top source of recruitment in the pass and may be utilized again.  
 
Contact with PCOS support groups  
Contact will be made with both national and local support groups to spread information about the study through informational brochures and/or participation in local meetings if necessary.  
 
Web sites  
The study will be prominently displayed on the local (Penn, PSU,  CHOP ) web site.  Additionally, each center will 
have a web page devoted to this study with general as well as contact information. Information will also be 
available at clinicaltrials.gov. Social Media and Craig slist will also be utilized, as this has been a proven source of 
recruitment in the past. For ads placed on social media, specifically F acebook and Instagram, they will be one -way 
adds and the study team will not directly interact with subjects on social media.  The ad will highlight a contact 
number for the interested individual to call to discuss the study.  Social media ads will be monitored by the University of Pennsylvania study coordinator to ensure they are properly being featured and not causing 
inappropriate comments. This monitoring will occur bi- weekly.  If any problems arise with the social media ad they 
will be immediately removed however this is not anticipated as they are one -way ads. This type of advertising has 
been previ ously used for studies within the department and has been well received.  
 
IRB Approval  
It is expressly acknowledged that all informational material that could be construed to be advertising will be approved by the central IRB prior to dissemination.  
 
Procedures for Tracking Sources of Subjects and their Disposition  
We will track all contacts from subjects interested in the study.  We will develop a pre -screening list that 
documents date and point of contact, eligibility based on telephone screening  or survey , and follow -up if subject 
meets prescreening and is interested in further participation.  The consent form may be mailed or emailed prior to the screening visit which is the next point of contact.  
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Obtaining Informed Consent 
Once potential women have been prescreened, they will be referred to the site clinical coordinator or his/her 
designee for a screening visit.  The consent process will be conducted according to each site’s standard operating procedures.   
Inclusion and exclusion criteria will be reviewed.  After the study has been completely explained to the woman, 
she will be given the informed consent documents to review.  Some individuals may wish to complete the informed consent process at the time of this discussion.  In these cases, the informed consent documents will be signed once all questions are resolved.  In other cases, the subjects may wish to take the consent forms home for further consideration.  In these cases, the coordinator will confirm t he woman’s willingness to be contacted, and set up a 
tentative timeframe to be back in touch with the subjects.  The consent can be signed once all questions have been answered to the satisfaction of the potential subject.  A signed informed consent document, approved by the central IRB, will be confirmed on all subjects prior to the baseline evaluation.   
In order to be eligible for enrollment and randomization, the woman must be confirmed to meet all inclusion and exclusion criteria described above.   
 
Intervention Group Assignment 
After screening is completed the information will be uploaded in RedCAP electronically, and randomization will be 
performed by IDS at the time of the randomization visit.   Subjects and study coordinators will not be informed of their treatment assignment.     
Study Interventions  
 
Interventions, Administration and Duration  
Study Medication:  All subjects will be randomized to receive either OCP + placebo, Metformin + placebo or OCP + 
Metformin for 24 weeks.  All medications will be self -administered.  Once eligibility has been confirmed and 
subjects have been randomized, the site staff will distribute appropriate medications during each visit. The subject will receive enough pills to last until the next visit (additional pills for each arm  will be distributed at the start of 
the study for situations if/when the visit window must be utilized; subjects will receive appropriate instructions regarding the extra medication). Subjects will be required to wash out of any excluded medications prior to enrollment in the study.  
 
Medication Compliance:  Medication bottles will be returned at visits 3 through 6  unless a remote visit is being 
conducted at the discretion of the PI . IDS will perform pill reconciliation during these visits to measure 
medication compliance. Medication compliance can also be assessed by reviewing the returned subject diaries. 
Compliance is assessed during the  monthly visits on site or remote contact with the subject.  Non -compliant 
subjects will be reminded of the importance of taking the medication properly.  
  
Life Style Modification (LSM):  In addition to taking study medication, all subjects will receive counseling (through 
the use of handouts) about diet and exercise at the randomization and 16 week visit.  The diet is based on the lifestyle modification protocol of the look AHEAD study an d POWER -UP trial. The study will follow the Diabetes 
Prevention Program recommendations for increasing physical activity.  A similar protocol was utilized in OWL -
PCOS and similar written materials will be provided to all subje cts in the current trial.  Assessment of dietary intake 
will be based on NCI created automated self- administered 24 -hour (ASA24) food recall tool.  This will allow us to 
access variability in dietary intakes in the 3 arms of the study.  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Cognitive Testing: All subjects will undergo cognitive functioning testing via the NIH Toolbox, a comprehensive 
set of neuro -behavioral measurements that quickly assesses cognitive, emotional, sensory, and motor function. 
Audio -recording of cognitive testing is optional (all recordings will be deleted after transcription).  The NIH 
Toolbox is assessing cognition for subject (age3 -85), thus eliminating a ceiling effect.  Staff will be trained to 
administer the tests. Training is performed online via the NIH Toolbox website. Any additional training or 
oversite will be done by a Clinical Neuropsychologist . During testing staff will audio record cognitive testing with 
subjects to verify answers given in a timely matter. All audio recordings will be consented for by the subject prior 
to recording and will remain on file for less than 24 hours at which point they will be deleted. One patient 
recording from each certified staff member will go to the Clinical Neuropsychologist to verify standardization. A 
description of the neuropsychological assessments includes:  
Neuropsych assessments:  
• Controlled Oral Word Association (COWA):  subjects must spontaneously name as many words as 
possible beginning with a given letter within a 60 second span.  
• Category fluency:  subjects must spontaneously name as many objects as possible that fit a given 
category within a 60 second span.  
• Logical memory:  subject is read the first story and recalls as many details as possible. The subject is then 
read a second story and must recall as many details as possible about that story; second story and recall 
is repeated. Following a delay of 25 -35 minutes, the sub ject must again recall as many details of each 
story as possible.  
• Digit Span:  subject is read a string of numbers and must repeat the numbers back to the examiner in 
either the exact same order (DS forward) or in reverse order (DS backward). Number strings increase in length by one number with each successful turn, and discontinued  when patient makes an error. Score is 
the longest string a patient can successfully repeat back.  
• Digit symbol substation:  Testing page shows a key at the top, which contains the numbers 1 -9, each 
paired with a special symbol. Below the key, subjects must fill in the numbers that match a grid of special symbols as quickly as possible, based on the key above.  
• Rey-Osterreith Figure:  subject copies the complex figure from the stimulus page. The stimulus is 
removed and the patient then immediately redraws as much of the figure as they can (immediate recall score).  
• Pegboard:  subject is tested with both dominant and non -dominant hands on how quickly they can fill in 
a pegboard. Each peg has a groove, which must be perfectly matched with the groove of the hole in order to fit. Score based on time to complete.  
• Trail making:  Numbers are scattered over a page and the subject must connect the numbers in 
numerical order; score derived from both number of errors and time to complete. Executive function can be tested by requiring patients to connect numbers in an alternating fashi on between two colors, 
i.e. yellow 1 -pink 2 -yellow 3 - pink 4, etc. Score still derived from both errors and time to complete.  
• Visual Puzzles:  Subjects are shown a 2D item that they are to imagine as a puzzle made from 3 pieces. 
The subject indicates which 3 pieces fit next to each other without stacking to make the given item. Each item has a 30 second time limit, with a discontinuation rule of  3 errors in a row.  The score is based on 
time and errors.  
 
Urine Pregnancy Test:  A urine pregnancy test will be performed for all subjects at every visit. If a positive result is 
found, the subject will be informed by site staff of positive result and offered resources regarding prenatal care or alternative options.  In the case of a p ositive pregnancy result, subjects will be withdrawn from the study.  In 
the case of a subject becoming pregnant, the subject will have the choice to consent to allow the study team to track until outcome of the pregnancy.  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
Vital Signs and Biometrics : Vital signs and b iometrics for this study include but are not limited to, measuring 
height and weight, blood pressure,  pulse, waist and hip circumference. Vital signs and biometrics will be 
collected at every visit except height which will only be recorded at the screening visit.  
Blood pressure and pulse will be measured in sitting position at all visits after the subject has rested for at least 
five minutes. Three blood pressure measurements will be taken 5 minutes apart and then averaged.  
  
Laboratory Evaluations : Blood will be collected at Screening, Randomization, week 16 and week 24 visits (early 
termination visit). Subjects will be required to be fasting prior to Screening, Randomization, week 16 and week 24 visit (nothing to eat or drink besides water for a minimum of 8 hours prior to blood draw). Subjects who have used hormonal contraception must wait at least 30 days prior to the collection of screening and fasting blood l tests. 
Screening blood tests that were completed within the last year can be substituted for laboratory tests collected at 
screening visit.  
 
Transvaginal Ultrasound:  Transvaginal ultrasound examinations will be performed at screening if indicated, 
randomization and 24 week visit (or early termination visit). The transvaginal ultrasound examinations will be performed according to the standard procedure for the center and include finding regarding the uterus, the endometrium and the ovaries.  
If a transvaginal probe is not tolerated, then transabdominal ultrasound may be used. 
The same procedures were used in the OWL -PCOS study and are well known by the centers.   
 
F-G Score:  The Ferriman -Gallwey score is a measure for quantifying hirsutism in women. The Primary 
Investigator (or designee , which may be the subject) will assess each subject’s  hirsutism using the Ferriman -
Gallwey scale at Screening, Randomization (if applicable and/or necessary) and 24 week visit.  During the 
assessment for hirsutism, the PI (or designee) will also assess the subject’s  acne.  
 
DXA:  DXA scans will be completed on each patient at Randomization Visit and 24 week visit. The scanning will 
include a whole body scan, the lumbar spine and both hips.    
Oral Glucose Test:  OGTT will be performed at the randomization and at 24 week visit. Prior to the OGTT subject 
must fast overnight for minimum of 8 hours. If subject is not fasting, the blood work must be rescheduled. Patients will receive 75 g of an oral glucose solution a t time zero (0) and blood will be sampled every 30 minutes 
for 2 hours for glucose, and insulin levels.  
 
PCOSQ:  The PCOSQ is a self -administered questionnaire for measuring health -related quality of life in women 
with PCOS. The PCOSQ will be administered to subjects at Randomization and 24 week visit.     
 
STAI: The STAI (State -Trait Anxiety index) is a questionnaire for  accessing trait anxiety and state anxiety.  The 
STAI will be administered to subjects at Randomization and 24 week visit.  
 
CES-D: The CES -D is a screening test for depressive  symptoms. The CES -D will be administered to subjects at 
Randomization and 24 week visit.  
 
FSDS- R: The FSDS -R (The Female Sexual Distress Scale -Revised) is a screening questionnaire for measuring 
sexually related personal distress in women with Female Sexual Dysfunction (FSD)  
 
FSFI:  The FSFI (Female Sexual Function Index) is a brief questionnaire measure of sexual function in women. It 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 was developed for the specific purpose of assessing domains of sexual function (e.g. sexual arousal, orgasm, 
satisfaction, pain) in clinical trials.  
 
ASA24 : The Automated Self- Administered 24 -Hour Dietary Assessment Tool (ASA24). This 24 -hour dietary recall 
captures detailed information about all foods, drinks, and supplements (including vitamins, minerals, herbals, and other dietary supplements) you consumed from midnight to midnight. You will be asked to complete this at 12 weeks and 24 weeks.  
 
Concomitant Interventions  
No other interventions, other than those specified in the protocol are allowed to treat PCOS or weight management during participation in the study.    
 
Adherence Assessment  
Adherence to the interventions will be monitored by the use of medication reconciliation, diary compliance and by monthly visits on site or contact with the subject.   
Clinical and Laboratory Evaluations  
 
Schedule of Evaluations  
 The table below summarizes the clinical and laboratory evaluations during the trial.  A description of the visits follows. Note, prior to the screening visit, subjects may prescreen for potential eligibility.  
 
Table 6: Study Visits and Procedures  
Study Visit Schedule  Screening  
(half of 
the visit 
as a 
remote 
option)  Randomization  Randomization 
Patient Contact 
(PC) 4 Week 
Visit  
(remote 
option)  8 Week 
Visit  
(remote 
option)  12 
Week 
PC 16 
Week 
Visit  20 
Week 
PC 24 
Week 
Visit  Early 
Termination 
Visit (> or 
equal to 12 
weeks of 
medication ) End 
of 
study 
PC 
Sign Informed Consent   x                     
Medical History 
Questionnaire  x                     
Screening labs  x*                     
DNA Sample    x                   
Safety Labs  x* x          x   x x   
Menstrual History   x x  x x  x  x x  
Urine Pregnancy Test  x x  x x  x  x x  
Vitals and Biometrics  x x   x x   x   x x   
Hirsutism Assessment  x x             x x   
Transvaginal Ultrasound  x* x             x x   
Fasting labs    x         x   x x   
OGTT labs    x             x x   
DXA Scan    x             x x   
Lifestyle Modification    x         x         
ASA 24            x     x x   
Acne Assessment    x             x x   
HRQOL – PCOS, STAI, 
CES-D, FSDS -R, FSFI &   x             x x   
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Cognitive testing 
Questionnaires  
Randomization    x                   
Dispense Medication/Log    x   x x   x         
Collect  
Medication/Log        x x   x   x x   
Review Concomitant 
Medications  x x x x x x x x x x x 
Review Adverse Events     x x x x x x x x x 
 
*As Needed  
 
 
Timing of Evaluations  
 
7.2.1 Screening visit:   
1. Obtain informed, signed consent from subject.  
• Subject must specifically be made aware of potential drug side effects and adverse outcomes.  
* Remote option for e -consent via REDCap , utilization of this option at PI discretion  
2. Complete medical assessment.  
• At the Screening Visit, a detailed general medical history for the former 6 months (longer in case 
of gynecological relevance) and history of concomitant diseases or interventions is to be reviewed and to be documented.  
* Remote option for completion, utilization  of this option  at PI discretion  
 
3. Must obtain and record menstrual history.  
• Determine need for medroxyprogesterone acetate  (if subject has had no menses in the last 3 
months)  
*
 Remote option for completion, utilization  of this option  at PI discretion  
 4. Perform urine pregnancy test.  
 
5. Record vital signs and biometrics  
 
6. Blood draw for both screening labs (as needed) and safety labs (as needed)  
  
6. Review Hirsutism (F- G) Score  
* Remote option for completion, utilization  of this option  at PI discretion  
 8. Transvaginal Ultrasound (if indicated)  
 9. Review electronic Medical Record (if available)  
• If subjects are patients through the University of Pennsylvania Health System or Hershey Medical Center, electronic medical records will be reviewed to verify eligibility. Screening blood laboratory tests that were completed within the last year can be substituted for laboratory tests collected at screening and randomization visit.  
   
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
Table 7: Screening Blood Tests  
 
Category  Tests  
Safety Labs**  Complete metabolic panel, lipid profile  
Screening Labs  TSH*, Prolactin*, HbA1c*, CBC*, 17OH Progesterone^, DHEAS^, 
Total Testosterone#,  
 
*If drawn within 1 year of screening, eligible for use to determine eligibility criteria.  
^ If drawn within lifetime prior to screening, eligible for use to determine eligibility criteria.  
# If FG≥ 6 (≥2 for women of Asian descent) do not need to draw lab. Eligibility criteria can be determined without this lab value.   
** If drawn within 2 months of screening, eligible for use to determine eligibility criteria. These safety  labs must be drawn at Randomization visit if not 
drawn at Screening visit.  
 
 
 
7.2.2 Randomization Visit:   
 
1. Review menstrual history  
 
2. Complete urine pregnancy test  
 3. Record vital signs and biometrics  
 4. Complete fasting blood draw and Safety labs (as needed)  
 
5. Optional whole blood draw for DNA testing  
 
6. Start the oral Glucose Tolerance Test (this may be first since the subjects are fasting)  
 
7. Review Lifestyle Modification Counseling  
 8. Complete PCOSQ, CESD -R, STAI, FSDS -R & FSFI  
 9. Cognitive testing  
 
10. Complete DXA scan  
 
11.  Transvaginal Ultrasound ( if indicated)  
 
12. Randomize into study arm  
 
13. Dispense Logs/Medications  
• Review medication instructions  
  *For more detailed information regarding the order in which study procedures should occur, please refer to the 
Manual of procedures.  
   *Complete patient contact with subject two weeks after this visit.  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
Table 1: Randomization Fasting Blood Tests  
 
Category  Tests  
Fasting blood Labs  Total and free T, Apo A, Apo B, Apo.C3, hsCRP, FFA, IL -1,IL-6,1L-
10, hsCRP, NMR lipoprotein analysis, HDL- C efflux, AMH, SHBG, 
TNF alpha, Estradiol  
 
7.2.3 Follow - Up Visits  
Follow up Visits will be scheduled as shown in Table 6. Initial visits are only one month apart to allow us to 
trouble shoot any side effects especially while increasing the metformin/placebo tablets to the full dose and ensure adherence with the protocol. Urine pregnancy test will be checked, adverse events assessed, study logs 
reviewed, and new medications and study logs will be dispensed at each visit.  After randomization and at 12 and 20 weeks adverse events, menstrual history, medication compliance wi ll be reviewed via patient contact. Patient 
contact has also been placed 2 weeks after randomization to ensure patients are taking the medication properly and have experienced no adverse side effects.
 
 
 Table 9: Follow - Up Visits  
 
Visit Ideal Date  Lower Window  
(- 1 week)  Upper Window  
(+ 1 week)  Out of Window Limit  
(+/- weeks)  
2 Weeks*  2 weeks  1 week  3 weeks  0 / 4 weeks  
4 Weeks   4 weeks  3 weeks  5 weeks  2 / 6 weeks  
8 Weeks   8 weeks  7 weeks  9 weeks  6 / 10 weeks  
12 Weeks*  12 weeks  11 weeks  13 weeks  10 / 14 weeks  
16 Weeks  16 weeks  15 weeks  17 weeks  14 / 18 weeks  
20 Weeks*  20 weeks  19 weeks  21 weeks  18 / 22 weeks  
24 Weeks  24 weeks  23 weeks  25 weeks  22 / 26 weeks  
25 Weeks*  25 weeks  24 weeks  26 weeks  23 / 27 weeks  
* Patient contact  
 
7.2.4 Week 4 Follow - Up Visit   
* Remote option for completing visit, utilization of this option  at PI discretion  
 
1. Collect menstrual log and review medical history  
 
2. Perform urine pregnancy test  
 
3. Record Vital signs and Biometrics  
 
4. Review Adverse Events  
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 5. Collect Logs/Medication  
 
6. Dispense Logs/ Medications  
 
 
 7.2.5 Week 8 Follow - Up Visit  
* Remote option for completing visit, utilization of this option  at PI discretion  
 
1. Collect menstrual log and review medical history  
 
2. Perform urine pregnancy test  
 
3. Record Vital signs and Biometrics  
 
4. Review Adverse Events  
 
5. Lifestyle Modification Assessment  
Instruction to subject that the ASA 24 (online diet diary recall assessment) to be completed prior to the 12 -week patient contact. 
 
6. Collect Logs/Medication  
 
7. Dispense Logs/Medications  
 
 
7.2.6 Week 12 patient contact  
This contact will be made to ensure subject compliance with medications, keeping study logs and to review any 
side effects.  
 
7.2.7 Week 16 Follow - Up Visit  
1. Collect menstrual log and review medical history  
 2. Perform urine pregnancy test  
 3. Record Vital signs and Biometrics  
 
4. Fasting optional blood draw and safety labs  
 
5. Lifestyle Modification Counseling  
 
6. Review Adverse Events  
 
7. Collect Logs/ Medication  
 
8. Dispense Logs/Medications  
 
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 7.2.8 Week 20 patient contact  
This contact will be made to ensure subject compliance with medications, keeping study logs and to review 
any side effects.  Instruction to subject that the ASA 24 (online diet diary recall assessment) to be completed 
prior to the 24 -week visit  
 
 
7.2.9 Week 24 Final Follow - Up Visit or Early Termination Visit  (≥ to 12 weeks  of being on study medication ) 
1. Collect menstrual log and review medical history  
 
2. Perform Urine pregnancy test  
 
3. Record vital signs and biometrics  
 
4. Review Hirsutism (F -G) Score/ Acne Assessment  
  
5. Fasting blood draw and safety labs  
 
6. Complete an oral Glucose Tolerance Test  
 
7. PCOSQ, CESD -R, STAI  
 
8. Review Hirsutism (F- G) Score/ Acne Assessment  
 
9. Complete DXA scan  
 
10. Obtain a Transvaginal Ultrasound (TVU)  
 
11. Review Adverse Events  
 
12. Collect Logs and medication  
 
13. Must obtain and record menstrual history  
 Determine need for medroxyprogesterone acetate  (if subject has had no menses during 
the course of this study)  
 
 
7.2.10 Week 25 patient contact  
This contact will be made one week after patient has completed taking the medication to review any side effects 
and answer any patient questions. This patient contact will close out the study adverse events.  
  
Study Risk and Benefits  
 
Risk  
The risks of these studies include the risks of the study procedures, and the risk of the study interventions.  
These will be discussed separately below.  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
Risks of Study Procedures  
These risks include the risk of phlebotomy, oral glucose tolerance test and DXA. The risks of phlebotomy include 
pain at the phlebotomy site, bruising and rarely bleeding, and potentially iatrogenic anemia.  Risks of the oral 
glucose tolerance test include the risks of multiple phlebotomy or in some cases the risk of insertion of an IV. The risks of IV insertion include the risks of phlebotomy, and additionally the induction of anemia, and infection at the site. Glucose ingestion can cause nausea and in rare instances vomiting upon ingestion. We have never experienced an allergic reaction to the oral glucose  solution, though this is possible. Some subjects also may 
experience an episode of hypoglycemia after the test which can present with increased heart rate and anxiety.  In the most severe cases, fainting can occur. The DXA scan will involve exposure to radiation, on average 2 -3 
milliroentgens of radiation during the procedure. The average amount of radiation that a person would receive from a DXA scan is less than 1% of the background radiation experienced from living in the Philadelphia area for 
one year, for example.  
 
Risks of Study Interventions   
Oral Contraceptive Pill  - OCP used in this study is low dose (20micrograms ethinyl estradiol), which may cause 
bloating, nausea, breast tenderness, mood changes, weight change and headaches.  Common side effects 
include breakthrough bleeding and amenorrhea.  OCP are also associated with increased risk for cardiovascular disease, especially venous thromboembolism and stroke. OCP can also cause hypertension and alter blood lipid and glucose levels.  Interactions with drugs such as phenobarbital, phenytoin, and rifampin increase the  
metabolism of oral contraceptives, thus decreasing the effectiveness as a method of birth control. Table lists all side effects recorded in women in the OCP arm of the recently completed OWL -PCOS study (n=49). Roughly 
same numbers are expected in this current study.  
 
OWL -PCOS study  
OCP side effects  Number of  
subjects (%)  OCP side effects  Number of  
subjects (%)  
Headache  14 (28.6)  Dizziness/Vertigo  2 (4.1)  
Upper Respiratory Infections  8 (16.3)  Fatigue  2 (4.1)  
OWL -PCOS  N (%)  Side effects  N (%)  
Nausea/Vomiting  7 (14.3)  Back Pain  1 (2.0)  
Breast Pain  10 (20.4)  Acne  1 (2.0)  
Abdominal Pain  1 (2.0)  Chest pain  1 (2.0)  
Dysmenorrhea  8 (16.3)  Dental abscess  1 (2.0)  
Constipation  1 (2.0)  Hot flushes  1 (2.0)  
Abnormal uterine bleeding  4 (8.2)  Elevated BP w/o hypertension  1 (2.0)  
Mood Swings  3 (6.1)  Gastroenteritis  1 (2.0)  
Gas/Bloating  2 (4.1)  Otitis media  1 (2.0)  
Musculoskeletal Pain  3 (6.1)  Anemia  1 (2.0)  
Vaginitis/Vulvitis  4 (8.2)  Visual Changes  1 (2.0)  
Pelvic Pain  3 (6.1)  Conjunctivitis  1 (2.0)  
Bunion  1 (2.0)  Hemorrhoids  1 (2.0)  
Myalgia/myositis  1 (2.0)  Bleeding, rectal  1 (2.0)  
Fever  1 (2.0)  Cholelithiasis  1 (2.0)  
Sweating excess  1 (2.0)  Galactorrhea  1 (2.0)  
 
Treatment with metformin XR  - Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, 
flatulence, metallic taste in the mouth and anorexia) are the most common reactions to metformin XR and 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 approximately 30% more frequent in women taking metformin XR compared to placebo.  These symptoms are 
generally transient and resolve shortly after initiation of treatment. These symptoms will be managed with a step down decrease in the daily metformin XR dose (1/2 to one tablet per day per week) until symptoms resolve.  These symptoms alone will not be a reason for withdrawal from the study unless a patient is unable to tolerate any dose of the medication. There is a small risk of lactic acidosis among women taking this medication.  This most commonly occurs in patients with poorly controlled diabetes and impaired renal function.  Vitamin B12 
deficiency has also been reported in metformin -treated adults with T2DM.  Women with these pre -existing 
medical problems will be excluded from the study as per the exclusion criteria. T he Table below shows adverse 
events from metformin use in women with PCOS in the PPCOS1 study and the same results are expected in this current study.  
 
PPCOS1 metformin Side effects  Metformin(N=208)  
Blood and lymphatic system disorders  1/208 (0.5%)  
Cardiac disorders  1/208 (0.5%)  
Congenital, familial and genetic disorders  0/208 (0.0%)  
Ear and labyrinth disorders  3/208 (1.4%)  
Endocrine disorders  2/208 (1.0%)  
Eye disorders  3/208 (1.4%)  
Gastrointestinal disorders  177/208 (85.1%)  
General disorders and administration site conditions  61/208 (29.3%)  
Immune system disorders  3/208 (1.4%)  
Infections and infestations  43/208 (20.7%)  
Injury, poisoning and procedural complications  3/208 (1.4%)  
Investigations  6/208 (2.9%)  
Metabolism and nutrition disorders  37/208 (17.8%)  
Musculoskeletal and connective tissue disorders  29/208 (13.9%)  
Nervous system disorders  108/208 (51.9%)  
Pregnancy, puerperium and perinatal conditions  0/208 (0.0%)  
Psychiatric disorders  41/208 (19.7%)  
Renal and urinary disorders  7/208 (3.4%)  
Reproductive system and breast disorders  84/208 (40.4%)  
Respiratory, thoracic and mediastinal disorders  24/208 (11.5%)  
Skin and subcutaneous tissue disorders  19/208 (9.1%)  
Surgical and medical procedures  0/208 (0.0%)  
Vascular disorders  33/208 (15.9%)  
  Protection Against Risks  
Risks of adverse events will be reduced by the study personnel and the investigators regularly monitoring participants’ progress, by oversight of the local IRBs and the DSMB (see section below).  
 
Clinical staff at each site  - Our reproductive endocrinology groups at UPenn and PSU staffs a daily infertility clinic 
that meets every day (365 days a year). The staffing doctor also covers inpatient responsibility and research aspects of our service. The subjects at UPenn will be seen in the WHCRC which is on the same floor and adjacent to the REI practice site. The daily clinic at PSU meets just below the GCRC where the subjects are studied. At both sites a physician is available at a moment’s notice to see a subject. Therefore, t he patients participating in the 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 trials will have access to same day consult or visit with an investigator involved in the study, regardless of 
weekends and holidays, for any potential problem that arises in a study. We have utilized this system successfully for a wide variety of clinical studies for over 10 years.  
 
Review at research meetings  - Both groups at UPenn and PSU currently hold weekly research meetings attended 
by all the research staff which allows for communication about study issues and problems with any subjects in the study.  In addition to the weekly site research meetings, the  entire investigative team will meet by phone 
conference monthly, Face to face meetings will be held 2 times a year, to discuss the results of patients’ most recent study assessments as well as any adverse events. The research co ordinators will inform the investigative 
team of any adverse medical events, or abnormal lab values, reported by study participants. All studies will be IRB approved and regular progress reports submitted to the IRB as well as adverse events (see below).  
 
Protection against Study Procedure Risks  
Phlebotomy  - risks are reduced by the use of skilled nurses or study personnel who have had extensive 
experience with phlebotomy. The risks of an OGTT are minimized by utilizing trained nursing personnel with investigator back -up during the test. They are experienced i n inserting IVs in  study subjects.  When we know of 
prior difficulties with these procedures, we will consult with Anesthesia to insert the IV and minimize pain and psychological trauma.  
 
DXA - The whole body radiation dose to a female during a DXA is <1 mRem. The human race is continually being 
exposed to radiation from natural and man -made sources. The dose of background radiation to each person is 
300- 400 mRem so the exposure for these measurements is a minimal increase in exposure. For comparison 
purposes, this is less radiation exposure than from a routine chest x -ray and it is comparable to the radiation 
exposure from cosmic ray exposure during an airplane flight across the United States.  The risk from this level of exposure is considered to be minimal. A negative pregnancy test will be obtained prior to these studies in all subjects. If an individual has participated in any other research study in the past 12 months that included expo sure to ionizing radiation, we will assess overall exposure to radiation. If it exceeds 500 mrem for the 
calendar year by participating in this study, the potential participant will be excluded or moved to a later recruitment wave. Total ionizing radiation  exposure will be evaluated with the help of the University of 
Pennsylvania and Penn State Radiation Protection Advisory Committees.  
  8.2.1 Protection against Risk of Study Interventions  
Study subjects will be carefully screened for medical problems prior to randomization. The risks of the medications used in this study will be lowered through education and frequent follow- up. Study subjects will be 
monitored monthly in person or by telephone for adverse reactions.  Only a limited supply of medication will be dispensed at each visit to encourage compliance with the protocol and prevent a prolonged exposure of an early gestation to medication.   
Oral Contraceptive Pill - We will exclude subjects with all absolute contraindications to OCP  including a history of 
thrombophlebitis, known or suspected clotting disorders, cerebrovascular or coronary artery disease or myocardial infarction, known or suspected uterine, cervical or breast neoplasia, history of a benign or malignant 
liver tumor that developed during the use of OCPs or other estrogen- containing products.  Additionally, we will 
exclude other relative contraindications as listed in the exclusion  criteria.  Smoking will not be an absolute 
contraindication.  Subjects will be counseled about the risks of OCP, and warning signs for serious adverse events 
including leg swelling, redness, pain, shortness of breath, racing heart, chest pain, severe and unremitting headache, unilateral weakness or speech disturbance. Subjects will have a scheduled visit or receive communication from the study team monthly and symptoms elicited and recorded as part of the visit.  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Worrisome signs will be reported to study physicians immediately for evaluation and management.  We will have 
a low threshold of suspicion for discontinuing medication.  We should note that we had no serious adverse 
events among 49 obese women randomized to a low dose OCP in the OWL -PCOS study (see table 2 for side 
effects above).  Although the OWL -PCOS study showed a significant increase in prevalence of MetS in the OCP 
arm, only a small proportion of subjects developed DM or hypertension (4.6% and 6.7% respectively after 16 weeks). A fasting glucose level will be evaluated at the 16 week visit and a value >200mg/dl will prevent a subject from continuing in the study. BP will be measured at each visit and a subject with BP>150/100mmHg x2 will be unable to continue in the study.  
 
Metformin - There is a small risk of lactic acidosis among women taking this medication. This most commonly 
occurs in patients with poorly controlled diabetes and impaired renal function. Women with these pre -existing 
medical problems will be excluded from the protocol as per the exclusion criteria. There have been reports of 
lactic acidosis induced by exposure to iodine -containing radiocontrast agents, such as those used for an 
intravenous pyelogram.  Metformin XR will be stopped prior to procedures involving exposure to radiocontrast 
agents to reduce the chance of developing lactic acidosis (one week prior to medication and resume one week after the test). The development of lactic acidosis for any reason will be a reason for discontinuing participation in the study. Metformin XR is pregnancy category B with no known human teratogenic risk and no known 
embryonic lethality in humans.  Metformin XR has been used throughout pregnancy in a number of studies with no adverse maternal or fetal effects.  If a subject is pregnant during any part of the study, her participation will be stopped.  
 
Preventing Pregnancy  - All subjects will be asked to use barrier contraception during this study.  Pregnancy tests 
will be performed at each in person study visit.  
 
Menstrual irregularity  - All subjects will be asked to keep detailed menstrual log and study coordinators and site 
PIs will review symptoms. Subjects may present with break through bleeding on the low dose OCP. Some subjects in the metformin arm may not have any menses during t he study period. We will induce menses by 
administering medroxyprogesterone acetate at the screening visit if a subject has not had menses for 3 months . 
There is no data to suggest that lack of menses in the metformin arm for 6 months will increase risk of  
endometrial hyperplasia. In fact, several studies have described the biological plausibility of metformin having a protective effect on the endometrium. If a subject has not had menses during the study, we will administer medroxyprogesterone acetate after  confirming a negative pregnancy test at the end of the study.  
 Potential Benefits of the Proposed Research to Human Subjects and Others  
The subjects in this study will not benefit directly. The results from the study can be applied in the future to patients who stand to benefit from this information.  
 
Importance of the Knowledge to be Gained    
The importance of this study is high for the following reasons:  
1. Both MetS and PCOS are major health problems and the risks of common treatments (OCP or metformin) on development of MetS are poorly understood.  
2. Knowledge gained from this investigation will identify optimal strategies for treatment of overweight/obese women with PCOS  
3. Understanding the underlying pathophysiology for alterations in metabolic risk with OCP or metformin use, will provide important information for future studies . 
 
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
   
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Statistical Considerations  
 
General Design Issues  
This will be a randomized, double -blind, double dummy clinical trial of three types of medication, OCP + placebo, 
metformin + placebo or OCP + metformin.  We will track all subjects to completion.  Subjects will be randomized 
1:1:1 to the three treatments.    
  
Randomization  
Randomization is a critical feature of a clinical trial because it prevents treatment -selection biases. The study 
statistician will develop the programs for the randomization; however, the final random seeds used to generate the randomization scheme will be prepared by a statistician in PSU’s Department of Public Health Sciences 
independent of the study in order to keep the study statistician blinded  as well. The randomization scheme for this 
study will use variable -size, random permuted blocks to ensure that the number of participants in each treatment 
arm is balanced after each set of B  randomized participants, where B is the block size. Furthermore, the 
randomization will be stratified by recruitment site (UPenn/PSU), race (AA/non -AA), and the presence of MetS at 
baseline (yes/no). Randomization to the metformin or OCP arms will use 1:1:1 allocation.  
 
Outcomes  
Primary Outcome Measurements  
The primary outcome for this trial is prevalence of MetS.  
Secondary Outcome Measurements  
We may assess change in HDL -C function, serum apolipoproteins, lipid particle size and number, body fat 
distribution, BMI, serum adipokines, HbA1c, glucose and insulin sensitivity, serum markers of inflammation, free 
fatty acids, androgens, quality of life parameters, cognitive testing and predictive factors for change in prevalence on MetS  
 Sample Size and Accruals  
Sample Size and Power Calculations  
The primary outcome of the COMET -PCOS trial will be to assess a linear trend in prevalence of MetS after 6 
months’ treatment over the 3 arms assuming a 30% prevalence of MetS at baseline (derived from PENN data and 
OWL -PCOS). We anticipate a 15% subject drop -out over the course of the trial (in OWL -PCOS it was 8.1% over 16 
weeks). Based on these assumptions, a sample s ize of 240 (80 per arm) will provide 80% statistical power to 
detect a linear trend in the prevalence of MetS over the 3 arms at the end of 6 months of 26% in the metformin arm, 40% in the OCP+metformin arm and 50% in the OCP arm using a two -sided test for  linear trend with a 
significance level of 0.05.  
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
 
   
Table 10: Sample size scenarios based on varying assumptions  
 
Proportion 
with MetS at 
the End of the 
Trial in 
Metformin 
Arm Proportion with 
MetS at the End 
of the Trial in 
OCP+Metformin  
Arm Proportion 
with MetS 
at the End 
of the 
Trial in 
OCP Arm   
Total 
Sample 
Size (0% 
Drop -out)  
Total 
Sample 
Size (15% 
Drop -out)  
 
 
Power 
(%)  
 
Type I 
Error (α)  
0.25 0.38 0.50 204 240 84 0.05 
0.25 0.38 0.52 204 240 89 0.05 
0.26 0.40 0.50 204 240 80 0.05 
0.26 0.40 0.52 204 240 86 0.05 
0.28 0.42 0.52 204 240 80 0.05 
 
Statistical Analysis  
Primary analyses will invoke an intent -to-treat paradigm, wherein all randomized subjects are included according 
to their randomized treatment arm, regardless of actual treatment received, protocol violations, etc. D ata will be 
summarized using descriptive statistics for continuous variables (mean, standard deviation, number of 
observations, and percentiles) and frequency statistics (frequencies and percentages) for categorical variables. The area under the curve (AUC ) for glucose and insulin from the OGTT will be calculated using the trapezoidal 
rule. Univariate and bivariate distributions will be inspected in order to address any missing data, inconsistent 
responses, outliers, and data entry errors. The sample size estimates have taken into consideration a participant drop -out of 15%; however, every ef fort will be made during the studies to minimize any drop -out. If, however, 
study attrition appears to be an issue, we will use the observed data to determine if patients who completed the study differed from those who did not. To control for potential confounding factors for the association of the 
treatment effects with the metabolic syndrome, we have stratified the randomization by recruitment site, race, and the presence of metabolic syndrome at baseline. Al though stratification may potentially yield unequal 
numbers between strata, within each individual stratum there will be approximately equal numbers and balance between treatment groups. All analyses will include these 3 randomization stratification factors as covariates in the statistical models. All hypothesis tests will be two -sided and all analyses will be performed using SAS 
software , version  9.4 (SAS Institute, Inc., Cary, NC) , R software (open source) , or Stata software, version 13 
(StataCorp LP, College Station, TX) .   
 For the primary outcome of the presence of the metabolic syndrome at the end of the 6 -month trial, logistic 
regression will be used with independent variables that include terms for the treatment arm and the 3 randomization stratification factors as covariates , with a contrast constructed to test for linear trend over the 
three treatment arms.  
 A variety of secondary continuous outcomes will be collected during this longitudinal trial. These secondary outcomes include serum androgens, cholesterol efflux (HDL -C function) parameters, serum apolipoproteins, lipid 
particle size and number, anthropometric measures (BMI, adipokines, biomarkers of inflammation (e.g., hsCRP), 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 measures of adipose tissue, abdominal adiposity , and quality of life measures (PCOSQ).  For these continuous 
outcomes, linear mixed -effects models will be fit to assess differences between the treatment arms with respect 
to changes in these outcomes over time. The independent variables in the model will be treatment arm, time, 
the interaction of treatment and time, and the 3 randomization stratification factors as covariates. From the mixed -effects models, contrasts will be constructed to test the hypotheses  of interest with respect to changes 
over time in the outcomes. Linear mixed -effects models are an extension of ordinary regression models that 
account for the between - and within -subject correlation inherent in longitudinal trials. Further, linear mixed -
effects models do not drop patients with incomplete data and are easily extended to nonlinear mixed- effects 
models for ordinal data  and count outcomes. Following our assessment of the initial fit of the models, we will 
add covariates to the models that correspond to other potential confounders (e.g., age) to assess their impact, if any, on the treatment effects. Residual diagnostics will be assessed to determine the appropriateness of the model fit and, if necessary, transformations of the response will be used to meet modeling assumptions. 
Differences in means and associated 95% confidence intervals (CIs) will be used to quantify the magnitude of the 
effects.  
 For any binary outcomes collected at each visit, analyses will be based on  generalized estimating equations (GEE) 
with a logit link, an extension of logistic regression that accounts for correlated data within -subjects inherent in 
longitudinal trials, with independent variables that include terms for the treatment arm, time, the interaction of 
treatment and time, and the 3 randomization stratification factors as covariates.  Following our assessment of the initial fit of the models, we will add covariates to  the models that correspond to other potential confounders 
(e.g., age) to  assess their impact, if any, on the treatment effects. The effect size will be quantified using the odds 
ratios (OR) and corresponding 95% CI.  
Accrual  
A total of 5 years will be required to complete the study after start up; 36 -month enrollment period (based on 3 
subjects per site/month x 2 sites), 1 -month screening/randomization period, 6 -month treatment period and time 
built in for data analysis and in terpretation.  
 
Data Collection, Monitoring and Adverse Experience Reporting  
 
Records to be kept  
Data will be collected prospectively by designated research personnel at each study site, supervised by the site PI. 
Original source documents will be kept in the study subject folder.  Well -designed data collection forms will be 
developed to minimize data collection and recording errors. Administrative forms will be designed, such as visit procedure checklists, to assist the research staff in complying with protocol procedures. We will be collecting a medical history on each subject. We will also be obtaining biometric data, clinical data (hirsutism), imaging data from ultrasound, DXA scanning and biochemical data from blood. All data are being collected solely for the purpose of research and do not become part of the subject’s medical record.   
 All tissue samples and images will be labeled with the code number assigned to each subject and only de -identified 
samples will be sent to laboratories for testing.  Specimens will be stored in Women’s Health Clinic Research 
Center’s freezers at UPenn and banked for batched analysis.  
 
Study data will be managed using REDCap (Research Electronic Data Capture), a secure web application designed 
to support data capture for research studies, providing user -friendly web- based case report forms, real- time 
data entry validation (e.g., for data types and range checks), audit trails, a randomization module,  and a de -
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 identified data export mechanism to common statistical packages (SPSS, SAS, Stata, R/S -Plus). The database is 
hosted at the University of Pennsylvania, which will be used as a central location for data management. REDCap 
data collection projects rely on a thorough study -specific data dictionary defined in an iterative self -documenting 
process by all members of the research team. REDCap is flexible enoug h to be used for a variety of types of 
research and provides an intuitive user interface for database design and data entry.  
Database access for REDCap is granted on a study -by-study basis. At the start of the trial when the database is 
created all research personnel will be given defined user roles and assigned a unique username and password. 
There is a 90 -day password update policy for all REDCap users.   The REDCap database sits behind an application 
firewall and the data is stored on a virtual machine at Penn which is backed -up nightly.  
Maintenance/Retention of site records  
In order to comply with Good Clinical Practice (GCP) requirements, the investigators must maintain the master patient log that identifies all patients entered into the study for a period of two years after the study ends so that 
the subjects can be identified by audit.  The PI must maintain adequate records pertaining to subjects’ files and 
other source data for a minimum of 5 years after completion of the study. Each clinical site will be responsible for ensuring study personal are trained and follow the data management guidelines of GCP and internal site policies.
 
Data Security  
Study staff will make clear that subjects are not obligated to participate in the study and that their answers will 
be held strictly confidential. Questionnaires will not contain any identifying information, thus, ensuring the confidentiality of subjects’ responses. Code numbers will be assigned to each subject to maximize anonymity when entering and analyzing data. Any linking list of patient names and codes will be maintained separately, and destroyed at the earliest possible time. Only the investigators and research staff at each individual study center will have access to this information for patients re cruited at that center. The second site and the research 
coordinator will not have access to the linking list. The security of the research project data will be maintained through network hardware and user authentication (usernames and passwords). Back -ups of the project data 
files will occur every night, with user data backed -up incrementally Monday through Thursday and complete 
back -ups every Friday. Archival back -ups, stored indefinitely, are cut on the last weekend of every month. All 
back -up data are s tored in a secure off -site location. The number and variety of back -ups ensure ample data 
redundancy and protection. In addition, each participant will be assigned a unique subject identification number. Only the study coordinators will have the log linking this identification number with the participant’s personal information.  
 
Adverse Event Reporting  
Serious Adverse Events  
All serious adverse events (SAEs) that occur from randomization through thirty days after the last dose of study medication must be reported.  A serious adverse event is defined as: fatal or immediately life -threatening; severely 
or permanently disabling; requiring or prolonging inpatient hospitalization; overdose (intentional or accidental); ; or, any event adversely affecting the study’s risk/benefit ratio. Additionally, any event that, based on appropriate medical judgment, may jeopardize the subject’s health and may require medical or surgical intervention to prevent one of the outcomes listed above is considered an SAE.  
 If an SAE occurs and is thought to be related to the study medication, the study medication will be discontinued.   
 The site PI will report the SAE by completing and signing the Serious Adverse Event Report Form Subjects will be 
identified by subject identification number only.  No other identifying information will be included on the form. 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 The site PI must determine and record on the SAE form whether the SAE is unanticipated or anticipated, and if it 
is related, possibly related, or unrelated to participation in the research.  
 The DSMB and FDA (as applicable) will be notified and provide a determination regarding the SAE.  
 These determinations will dictate timeframes for sites’ submission to the DSMB ( Table 12 ): 
 
Table 11: Types of Serious Adverse Events and their reporting requirements  
TYPE  SITE  
Unanticipated and related/possibly 
related SAE, fatal or life -
threatening  Report to DSMB within 1 business 
day of discovery  
 
Other unanticipated and 
related/possibly related SAE  Report to DSMB within 1 business 
day of discovery  
Anticipated and related/possibly 
related SAE  Report to DSMB within 5 business 
days of discovery  
Unrelated SAE (anticipated or 
unanticipated Report to DSMB within 10 business 
days (no more than 3 weeks) of 
discovery  
 
 
Upon receiving notification of an SAE, the DSMB will review it via a closed -session email or conference -call 
discussion.   
The PI will evaluate the frequency and severity of the SAEs and determine if modifications to the protocol and consent form are required. Site PIs will report the SAE to their site IRB according to local IRB requirements.  
 Adverse events deemed non -serious will also be recorded throughout study participation from the start of study 
drug through one week after the last dose of study medication.  If an anticipated serious adverse event occurs at a frequency greater than expected, the DSMB will be notify the PI by the end of the next business day of discovery and follow the procedures for reporting serious and unanticipated and related adverse events.   If an adverse event not initially determined to be reportable to the FDA und er 21CFR312.32 is so reportable, the PI will report the 
adverse event to the FDA within 15 calendar days after the determination is made.  
 Data Monitoring  
There will be no pre -determined stopping rules and no interim analysis.  
 
Study Monitoring  
A monitoring plan that satisfies the ICH/GCP guidelines for clinical monitoring will be used. The Penn designated monitor at the Women’s Health Clinical Research Center, will lead this effort, and report findings to the PI of both sites and the DSMB when necessary. The Penn designated monitor  will have full knowledge of the study protocol, 
Manuals of Procedures, and is familiar with the database system redcap and is trained to review patient charts. The Penn designated monitor  along with the Project Manag er/Lead Study Coordinator at each site will be 
responsible for training and supervising other personnel.  
Once personnel at participating site are trained to recruit patients, the Penn designated monitor  will be sent to 
the site to help initiate the study according to the study protocol, and to ensure that the clinical site meets the scientific, clinical, and regulatory requirements. For example, the Penn designated monitor  will review all signed 
and dated forms (such as financial disclosure forms), the curriculum vitae and certifications of the investigators and personnel, CRF training, and the written IRB approval of the protocol and consent form.   
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 The Penn designated monitor  will return to the clinical site after a defined number of patients are recruited 
(recruitment of the first 5 patients) and yearly thereafter.  
During the site visit, the clinical sites should provide to the monitor (s) a space and access to all relevant records 
including medical records and regulatory binders, and there would be immediate verbal feedback provided to the 
site after original source documents are compared to entries in the CRF. The clinical sites must ag ree to cooperate 
with the monitor to ensure that any problems detected in the course of these monitoring visits are resolved. The on-site monitor will conduct an audit of a random sample of entered information against the source documents, 
a review of all regulatory documents, a review of all informed consents, and a review of all pharmacy logs.  The 
clinical site PI and study coordinator should be available to meet the monitor during the visit. The monitor will review electronic data from all sites, providing a method for identifying systematic errors or problems.  
To assure Good Clinical/Laboratory Practice,  the monitor will control adherence to the protocol at the clinical sites 
and evaluate the competence of the personnel at the clinical sites including the ability to obtain written informed 
consents and record data correctly. The monitor will inform the PI , and DSMB regarding problems relating to 
facilities, technical equipment, or medical staff. A thorough written report will follow each site -visit and will include 
a detailed itemization of discrepancies and items requiring follow -up or reconciliation. The monitor will be 
responsible for maintaining regular contacts between the investigators in the clinical sites. When the study ends, 
the monitor will also visit the clinical site to provide assistance for close -out. 
 
 
Human Subjects Protection 
 
Institutional Review Board (IRB) Review and Informed Consent  
This protocol and the informed consent document and any subsequent modifications will be reviewed and 
approved by the IRB responsible for oversight of the study.  A signed consent form will be obtained from the 
subject. The consent form will describe the purpose of the study, the procedures to be followed, and the risks 
and benefits of participation.  A copy of the consent form will be given to the subject, and this fact will be documented in the subject’s record.  
 Subject Confidentiality  
All laboratory specimens, evaluation forms, reports, and  other records that leave the site will be identified only 
by the Study Identification Number (SID) to maintain subject confidentiality.  All records will be kept in a locked file cabinet.  All computer entry and networking programs will be done using SIDs  only to prevent the loss of 
confidentiality.  Clinical information will not be released without written permission of the subject, except as necessary for monitoring by IRB, the OHRP, the sponsor, or the sponsor’s designee.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains the 
ability to use all information collected prior to the revocation of subject authorization. For subjects that have revoked authorization to  collect or use PHI, attempts should be made to obtain permission to collect at least vital 
status (i.e. that the subject is alive) at the end of their scheduled study period  
  Study Modification/Discontinuation  
The study may be modified or discontinued at any time by the IRB, the NIH, the OHRP, or other government agencies as part of their duties to ensure that research subjects are protected.  
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 Data and Safety Monitoring Board  
 
Kathy Hoeger from the University of Rochester Medical Center will chair the DSMB for this clinical trial.  The 
DSMB will review safety information, especially SAEs that may occur, on a quarterly basis while the study is active and ongoing.  Kathy will be consulted for any safety questions that may arise during the trail.  
 
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 References  
 
1 Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS 
phenotypes based on the Rotterdam criteria. Fertil Steril. 2007 Nov;88(5):1389-95. 
 
2 Wild RA, Carmina E, Diamanti- Kandarakis E, Dokras A, Escobar -Morreale HF, Futterweit W, Lobo  R, 
Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease 
in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010 May;95(5):2038-49. 
 
3Panidis D, Tziomalos K, Misichronis G, Papadakis E, Betsas G, Katsikis I, Macut D. Insulin resistance and 
endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum 
Reprod 2012; 27:541-549 
 
4 Després JP, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C. 
Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk 
Factors, Exercise Training, and Genetics (H ERITAGE) family study. Arterioscler Thromb Vasc Biol. 2000 
Aug;20(8):1932-8. 
 
114 Katzmarzyk PT, Bray GA, Greenway FL, Johnson WD, Newton RL Jr, Ravussin E, Ryan DH, Smith SR, 
Bouchard C.Racial differences in abdominal depot-specific adiposity in white and African American adults. Am 
J Clin Nutr. 2010 Jan;91(1):7-15. 
 
5 Hillman JK, Johnson LN, Limaye M, Feldman RA, Sammel M, Dokras A Black women with polycystic ovary 
syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white 
women with PCOS [corrected].Fertil Steril. 2014 Feb;101(2):530-5 
 
6 Hillman JK, Johnson LN, Limaye M, Feldman RA, Sammel M, Dokras A Black women with polycystic ovary 
syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white 
women with PCOS [corrected].Fertil Steril. 2014 Feb;101(2):530-5 
 
7 Legro RS, Dodson WC, Kris- Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk 
CL, Estes SJ, Fleming J, Allison KC, Sarwer DB, Coutifaris C, Dokras A . Randomized 
Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary 
Syndrome. J Clin Endocrinol Metab. 2015 Nov;100(11):4048-58 
 
  
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
 
8 Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A.Increased risk of depressive disorders in 
women with polycystic ovary syndrome. Fertil Steril. 2007 Jun;87(6):1369-76. 
 
9Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental health disorders in women 
with polycystic ovary syndrome: a longitudinal study.Fertil Steril. 2009 Jan;91(1):207-12 
 
10 Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de 
Lemos JA, Shaul PW. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 
2014 Dec 18;371(25):2383-93. 
 
11Khera AV, Cuchel M, laLleraMoya M, Rodrigues A, Burke MF, Jafri K,French BC, Phillips JA, Mucksavage 
M L, Wilensky RL, Mohler ER, Rothblat GH,Rader  DJ Cholesterol efflux  capacity,  high-density lipoprotein  
function, and atherosclerosis. N Engl J Med. 2011;364:127–135. 
 12 
Roe A, Hillman J, Butts S, Smith M, Rader D, Playford M, Mehta NN , Dokras A . Decreased 
cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS.J Clin Endocrinol 
Metab. 2014 May;99(5):E841-7 
 
13 Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris 
C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER; Clomiphene, 
metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356(6):551-66 
 
14Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic 
dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001; 135: 447–459 
 
15 Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the 
acute control of very low density lipoprotein production in humans. J Clin Invest . 1995; 95: 158–166. 
 
 
16 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- alpha: direct role 
in obesity-linked insulin resistance. Science 1993;259:87–91. 
 
17 Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating 
factors and other mediators of inflammation.Mol Biol Med 1990;7:147–59.  
 
18 Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Risk Factor 
and Life Expectancy Research Group. Am J Epidemiol. 1998;148(10):958-66. 
 19 
Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for 
prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Archives of Internal Medicine. 
2005;165:2644–2650. 
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 20 Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review 
and meta-analysis. J Am Coll Cardiol 2010;56:1113–32. 
 
21 Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men 
and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73–8. 
 22 
Devers MC, Campbell S, Simmons D. Influence of age on the prevalence and components of the metabolic 
syndrome and the association with cardiovascular disease. BMJ Open Diabetes Res Care. 2016 Apr 25;4(1) 
 
23 Dokras A , Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic 
ovary syndrome for metabolic syndrome.Obstet Gynecol. 2005 Jul;106(1):131-7. 
 
24Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome 
in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update.2010; 16(4):347-63. 
 
25 Escobar -Morreale HF, Luque-Ramírez M, González F.Circulating inflammatory markers in polycystic ovary 
syndrome: a systematic review and metaanalysis.Fertil Steril. 2011 Mar 1;95(3):1048-58. 
 26
Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, 
Poulasouchidou M, Tzellos TG, Makedos A, Chourdakis M, Tarlatzis BC.Meta- analysis of cardiovascular 
disease risk markers in women with polycystic ovary syndrome.Hum Reprod Update. 2011 Nov-
Dec;17(6):741- 60 
 
27 Dokras A .Cardiovascular disease risk in women with PCOS.Steroids. 2013 Apr 26. 
 
28 Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE. 
Menstrual   cycle   irregularity   and   risk for   future   cardiovascular   disease.  J   Clin   Endocrinol Metab  
2002;87(5):2013-2017. 
 
29Mani H, Levy MJ, Davies MJ, Morris DH, Gray LJ, Bankart J, Blackledge H, Khunti K, Howlett TA. Diabetes 
and cardiovascular events in women with polycystic ovary syndrome: a 20 -year retrospective cohort study. Clin 
Endocrinol (Oxf). 2013 Jun;78(6):926-34. 
 
30 Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic 
ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005;90(8):4650-8. 
 
31Dokras A , Clifton S, Futterweit W, Wild R Increased risk for abnormal depression scores in women with 
polycystic ovary syndrome: a systematic review and meta-analysis..Obstet Gynecol. 2011 Jan;117(1):145-52. 
 
32 Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. 
Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin 
Endocrinol Metab. 2013 Dec;98(12):4565-92 
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 33 ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol. 2009 Oct;114(4):936-49. 
ACOG Committee on Practice Bulletins --Gynecology. 
 
34 Rotterdam ESHRE/ASRM -sponsored PCOS consensus workshop group. Revised 2003 consensus on 
diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 
2004;1:41–7. 
 
35 Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral 
contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in 
polycystic ovary syndrome. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005552. Review. 
 
36 Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet 
Gynaecol 2004;18(5):737-54. 
 37 
Corbould A Effects of androgens on insulin action in women: is androgen excess a component of female 
metabolic syndrome? Diabetes Metab Res Rev. 2008 Oct;24(7):520-32. 
 38
Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Hennekens CH and Speizer FE 
(1992) Oral contraception use and the risk of type 2 diabetes in a large prospective study of women. 
Diabetologia 35,967–972. 
 
39 Watanabe RM, Azen CG, Roy S, Perlman JA, Bergman RN. Defects in carbohydrate metabolism in oral 
contraceptive users without apparent metabolic risk factors. J Clin EndocrinolMetab 1994;79:1277–1283  
 
40 Chasen -Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman Dand Manson JE. A 
prospective study of oral contraceptives andNIDDM among U.S. women. Diabetes Care 1997; 20,330–
335. 
 
41 van Rooijen M, Hansson LO, Frostegård J, Silveira A, Hamsten A, Bremme K Treatment with combined oral 
contraceptives induces a rise in serum C -reactive protein in the absence of a general inflammatory response. J 
Thromb Haemost. 2006 Jan;4(1):77-82. 
 
42 Krintus M, Sypniewska G, Kuligowska-Prusinska M. Effect of second and third generation oral 
contraceptives on C-reactive protein, lipids and apolipoproteins in young, non-obese, non-smoking apparently 
healthy women. Clin Biochem. 2010 Apr;43(6):626-8. 
 
43 Ball MJ, Ashwell E, Jackson M, Gillmer MD Comparison of two triphasic contraceptives with different 
progestogens: effects on metabolism and coagulation proteins..Contraception. 1990 Apr;41(4):363-76. 
 44 
Van Rooijen M, Schoultz BV, Silveira A, Hamsten A and Bremme K (2002) Different effects of oral 
contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am 
J Obstet Gynecol 186,44–48. 
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 45 Halperin IJ, Kumar SS, Stroup DF, Laredo SE The association between the combined oral contraceptive pill 
and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic 
review and meta-analysis of observational studies..Hum Reprod. 2011 Jan;26(1):191-201 
 
46Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989 Profound peripheral insulin resistance, independent of 
obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174 
 
47 Ciaraldi TP, el -Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SS 1992. Cellular mechanisms of insulin 
resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 75(2):577-83. 
 
48 Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E 2001. Defects in insulin receptor signaling in vivo in the 
polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 281(2):E392-9. 
 49
Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR 2009. Polycystic ovary syndrome is associated 
with tissue -specific differences in insulin resistance. J Clin Endocrinol Metab 94(1):157-63. 
 
50 Rosenbaum D, Haber RS, Dunaif A 1993. Insulin resistance in polycystic ovary syndrome: decreased expression 
of GLUT -4 glucose transporters in adipocytes. Am J Physiol 264(2 Pt 1):E197-202. 
 
51Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome --a reappraisal 
Nat Clin Pract Endocrinol Metab. 2008 May;4(5):272-83. 
 
52 Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–9. 
 
53 Knowler WC, Barrett -Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Reduction inm  
the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research 
Group. N Engl J Med. 2002 Feb 7;346(6):393-403. 
 
54 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 
diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. [No authors listed]Lancet. 1998 Sep 
12;352(9131):854-65. 
 
55Quinn SM, Baur LA, Garnett SP, Cowell CT. Treatment of clinical insulin resistance in children: a systematic 
review. Obes Rev. 2010;11(10):722–30. 
 56
Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Ivison F, et al. Metformin in obese children and adolescents: 
the MOCA Trial. J Clin Endocrinol Metab. 2013;98(1):322–9. A randomized trial which assessed the effect of 
metformin on body weight, metabolic risk factors, and adipokines in obese children and adolescents with hyperinsulinemia and/or impaired fasting glucose or impaired glucose tolerance. 
 
57 Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.Insulin-sensitising drugs (metformin, rosiglitazone, 
pioglitazone, D- chiro -inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 subfertility. Cochrane Database Syst Rev. 2012 May 16;5:CD003053. doi: 
10.1002/14651858.CD003053.pub5. Review.  
 
58 J.M. Lord, I.H. Flight, R.J. Norman, Metformin in polycystic ovary syndrome: systematic review and meta- 
analysis. Br. Med. J. 327, 951–953 (2003) 
 
59 Nieuwenhuis- Ruifrok AE1, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ. Insulin sensitizing drugs for 
weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. 
Hum Reprod Update. 2009 Jan-Feb;15(1):57-68 
 
60 Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta- analysis: metformin treatment in persons at risk for 
diabetes mellitus..Am J Med. 2008 Feb;121(2):149-157 
 
61 Morin -Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS Metformin reduces serum 
C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Oct;88(10):4649-54. 
 
62 Thethi TK, Katalenich B, Nagireddy P, Chabbra P, Md NK, Fonseca V.Role of insulin sensitizers on 
cardiovascular risk factors in polycystic ovarian syndrome – a meta -analysis.Endocr Pract. 201 
Jun;21(6):645-67 
 
63 Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ.Metformin and lifestyle 
modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015 
Sep-Oct;21(5):560-74. 
 
64 Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N Insulin-sensitising drugs versus the combined oral 
contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in 
polycystic ovary syndrome..Cochrane Database Syst Rev. 2007 
 
65 Morin -Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and 
metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000 Sep;85(9):3161-8. 
 
66 Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol- 
cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol. 2005 Feb;152(2):269-75. 
 
67 Harborne L, Fleming R, Lyall H, Sattar N, Norman J Metformin or antiandrogen in the treatment of hirsutism 
in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Sep;88(9):4116-23. 
 
68 Luque- Ramírez M, Alvarez -Blasco F, Escobar- Morreale HF. Antiandrogenic contraceptives increase serum 
adiponectin in obese polycystic ovary syndrome patients. Obesity (Silver Spring). 2009 Jan;17(1):3-9. 
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 69 Moran LJ, Meyer C, Hutchison SK, Zoungas S, Teede HJ.Novel inflammatory markers in overweight women 
with and without polycystic ovary syndrome and following pharmacological intervention. J Endocrinol Invest. 
2010 Apr;33(4):258-65. 
 
70Glintborg D, Mumm H, Altinok ML, Richelsen B, Bruun JM, Andersen M. Adiponectin, interleukin -6, monocyte 
chemoattractant protein -1, and regional fat mass during 12- month randomized treatment with metformin and/or 
oral contraceptives in polycystic ovary syndrome.J Endocrinol Invest. 2014 Aug;37(8):757-64. 
 
71 Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M.Body composition is improved 
during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab. 2014 Jul;99(7):2584-91   
 
72Cussons AJ, Stuckey BG, Walsh JP, Burke V & Norman RJ Polycystic ovarian syndrome: marked 
differences between endocrinologists and gynaecologists in diagnosis and management. Clinical 
Endocrinology 2005 62 289–295. 
 
73 Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, 
Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz B; ESE PCOS Special Interest 
Group.European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Gro up's Questionnaire. Eur J Endocrinol. 2014 Oct;171(4):489-98. 
 
74Bonny AE, Appelbaum H, Connor EL, Cromer B, DiVasta A, Gomez-Lobo V, Harel Z, Huppert J, Sucato G; 
NASPAG Research Committee. Clinical variability in approaches to polycystic ovary syndrome. J Pediatr 
Adolesc Gynecol. 2012 Aug;25(4):259-61. 
 
75Misso M, Boyle J, Norman R, Teede H.Development of evidenced-based guidelines for PCOS and 
implications for community health.Semin Reprod Med. 2014 May;32(3):230-40. 
 
76 Domecq JP, Prutsky G, Mullan RJ, Hazem A, Sundaresh V, Elamin MB, Phung OJ, Wang A, Hoeger K, 
Pasquali R, Erwin P, Bodde A, Montori VM, Murad MH Lifestyle modification programs in polycystic ovary 
syndrome: systematic review and meta -analysis.  
 
77 Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010;375:181–3. 
 
78 Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen 
replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196- 1204. 
 
79 Tikkanen MJ, Nikkila EA, Kussi T, Sipinens S. High density lipoprotein- 2 and hepatic lipase: reciprocal 
changes produced by estrogen and norgestrel. J Clin Endocrinol Metab. 1982;54:1113-1117. 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
80Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif 
JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in 
patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122 
 
81 Khera AV, Patel PJ, Reilly MP, Rader DJ.The addition of niacin to statin therapy improves high-density 
lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol. 2013 Nov 12;62(20):1909-
10. 
 
82 Badeau RM, Metso J, Kovanen PT, Lee-Rueckert M, Tikkanen MJ, Jauhiainen M. The impact of gender and 
serum estradiol levels on HDL-mediated reverse cholesterol transport. Eur J Clin Invest. 2013 Apr;43(4):317- 23 
 
83 McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat 
GH, Reilly MInflammation impairs reverse cholesterol transport in vivo.Circulation. 2009 Mar 
3;119(8):1135-45. 
 
84Matsuki K, Tamasawa N, Yamashita M, Tanabe J, Murakami H, Matsui J, Imaizumi T, Satoh K, Suda T 
Metformin restores impaired HDL -mediated cholesterol efflux due to glycation. Atherosclerosis. 2009 
Oct;206(2):434-8. 
 
85Sarwar N, Danesh J, Eiriksdottir G, et Triglycerides and the risk of coronary heart disease: 10,158 incident 
cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–45 
 
86 Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A Loss-of-function mutations in APOC3 
and risk of ischemic vascular disease.. N Engl J Med. 2014 Jul 3;371(1):32-41 
 
87 Watson TD, Caslake MJ, Freeman DJ, Griffin BA, Hinnie J, Packard CJ, Shepherd J. Determinants of LDL 
subfraction distribution and concentrations in young normolipidemic subjects. Arterioscler Thromb. 1994; 
14:902–9 
 
88 Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 
2002; 43: 1363–1379. 
 89 
Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and 
concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010 
May;59(5):1153-60 
 
90 Goff DC Jr, D’Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein 
size and subclass concentrations: results from the Insulin Resistance Atherosclerosis Study. Metabolism. 2005; 
54: 264–270. 
 
91 Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. 
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration 
determined by nuclear magnetic resonance. Diabetes. 2003; 52: 453–462. 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
92 Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald 
calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009 
May;55(5):888-94. 
 
93 Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, Arakaki R, Watson K, Horton E, 
Barrett -Connor E Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in 
the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013 Oct;98(10):3989-98. 
 94  
InterAct Consortium, Langenberg C, Sharp SJ, Schulze MB, Rolandsson O, Overvad K, Forouhi NG, Spranger 
J, Drogan D, Huerta JM, Arriola L, de Lauzon-Guillan B, Tormo MJ, Ardanaz E, Balkau B, Beulens JW, Boeing 
H, Bueno-de- Mesquita HB, Clavel -Chapelon F, Crowe FL, Franks PW, Gonzalez CA, Grioni S, Halkjaer J, 
Hallmans G, Kaaks R, Kerrison ND, Key TJ, Khaw KT, Mattiello A, Nilsson P, Norat T, Palla L, Palli D, Panico S, Quirós JR, Romaguera D, Romieu I, Sacerdote C, Sánchez MJ, Slimani N, Sluijs I, Spijker man AM, Teucher 
B, Tjonneland A, Tumino R, van der A DL, van der Schouw YT, Feskens EJ, Riboli E, Wareham NJ. Long- term 
risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC- InterAct case-cohort 
study. PLoS Med. 2012;9(6):e1001230. 
 
95 Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, 
Thompson A, Sarwar N, Kizer JR, Lawlor DA, Nordestgaard BG, Ridker P, Salomaa V, Stevens J, Woodward 
M, Sattar N, Collins R, Thompson SG, Whitlock G, Danesh J.Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011 Mar 26;377(9771):1085-95 
 
96 Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic 
review and meta-analysis. Obes Rev. 2013 Feb;14(2):95-109. 
 
97 Faloia E, Canibus P, Gatti C, Frezza F, Santangelo M, Garrappa GG, Boscaro M2004 Body composition, fat 
distribution and metabolic characteristics in lean and obese 
 
98 Barber, T.M., Golding, S.J., Alvey, C., Wass, J.A., Karpe, F., Franks, S., McCarthy, M.I., Global 
adiposity rather than abnormal regional fat distributioncharacterises women with polycystic ovary 
syndrome. 2007. J.Clin. Endocrinol.Metab. 93, 999–1004. 
 
99 Mannerås -Holm L, Leonhardt H, Kullberg J, et al. Adipose tissuehas aberrant morphology and function in 
PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated 
with insulin resistance. J Clin Endocrinol Metab. 2011;96:304–311. 
 
100 Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, Di Fede G, Rini G. Abdominal fat 
quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin 
resistance. J Clin Endocrinol Metab. 2007 Jul;92(7):2500-5. 
 
101 Svendsen PF, Nilas L, Nørgaard K, Jensen JE, Madsbad S. Obesitybody composition and metabolic 
disturbances in polycystic ovarysyndrome. Hum Reprod. 2008;23:2113–2121. 
 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
 102 Puder, J.J., Varga, S., Kraenzlin, M., De Geyter,C.,Keller, U., Muller, B., 2005. Central fat excess in 
polycystic ovary syndrome: relation to low -grade inflammation and insulin resistance. J. Clin. Endocrinol. 
Metab. 90, 6014–6021. 
 
103van de Woestijne AP, Monajemi H, Kalkhoven E, Visseren FL. Adipose tissue dysfunction and 
hypertriglyceridemia: mechanisms and management. Obes Rev. 2011 Oct;12(10):829-40. 
 
104 Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents anwomen 
with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin 
Endocrinol Metab. 2004 Apr;89(4):1592-7. 
 
105Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO.Body composition in lean women with polycystic 
ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception. 2013 
Mar;87(3):358-62.  
 
106 Ibáñez L, Díaz M, Sebastiani G, Marcos MV, López- Bermejo A, de Zegher F.Oral contraception vs insulin 
sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C - 
reactive protein, intima -media thickness, viscer al adiposity, insulin sensitivity, and menstrual regularity. J Clin 
Endocrinol Metab. 2013 May;98(5) 
 
107Diamanti-Kandarakis E, Dunaif A Insulin resistance and the polycystic ovary syndrome revisited: an update 
on mechanisms and implications. Endocr Rev. 2012 Dec;33(6):981-1030. 
 108 
Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Pubertal metformin therapy to reduce total, 
visceral, and hepatic adiposity. J Pediatr. 2010 Jan;156(1):98-102 
 109
Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the 
metabolic syndrome in women with polycystic ovary syndrome --a randomised, double-blind, placebo-
controlled trial. BJOG. 2006 Jul;113(7):817-24. 
 
110 R. Pasquali, A. Gambineri, D. Biscotti, V. Vicennati, L. Gagliardi, D. Colitta, S. Fiorini, G.E. Cognigni, 
M. Filicori, A.M. Morselli- Labate, Effect of long -term treatment with metformin added to hypocaloric diet 
on body composition, fat distribution, androgen and insulin levels, in abdominally obese women with and 
without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85, 2767–2774 (2000) 
 
111 Maffei, M., Halaas, J., Ravussin, E., Pratley, R.E., Lee, G.H., Zhang, Y., Fei, H., Kim, S., Lallone, R., 
Ranganathan, S., 1995. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in 
obese and weight-reduced subjects. Nat. Med. 1, 1155–1161. 
 
 
112 Barber TM, Franks S Adipocyte biology in polycystic ovary syndrome..Mol Cell Endocrinol. 2013 
Jul 5;373(1-2):68-76. 
 
 
113 Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT Adiponectin multimeric complexes and the 
metabolic syndrome trait cluster..Diabetes. 2006 Jan;55(1):249-59. 
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  
114  Toulis, K.A., Goulis, D.G., Farmakiotis, D., Georgopoulos, N.A., Katsikis, I., Tarlatzis, B.C., Papadimas, I., 
Panidis, D., 2009. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-
analysis. Hum. Reprod. Update 15, 297–307. 
 
115 Tarkun I, Dikmen E, Cetinarslan B, Cantürk Z.Impact of treatment with metformin on adipokines in patients 
with polycystic ovary syndrome.Eur Cytokine Netw. 2010 Dec;21(4):272-7. 
 
116 Singh S, Akhtar N, Ahmad J. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of 
metformin treatment in a case -control study. Diabetes Metab Syndr. 2012 Oct-Dec;6(4):207-11. 
 
117 Esfahanian F, Zamani MM, Heshmat R, Moini nia F. Effect of metformin compared with hypocaloric diet on 
serum C -reactive protein level and insulin resistance in obese and overweight women with polycystic ovary 
syndrome. J Obstet Gynaecol Res. 2013 Apr;39(4):806-13. 
 
118 Luque- Ramírez M, Escobar -Morreale HF. Treatment of polycystic ovary syndrome (PCOS) with metformin 
ameliorates insulin resistance in parallel with the decrease of serum interleukin -6 concentrations. Horm Metab 
Res. 2010 Oct;42(11):815-20
COMET -PCOS PROTOCOL V 10.1     NOVEMBER 30 , 2021 
  